Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8892677,trough,"The median trough and peak blood levels of SDZ PSC 833 ranged from 461/1134 ng/ml at 5 mg/kg/day to 821/2663 ng/ml at 15 mg/kg, respectively.","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [ml],461,275,DB00541,Vincristine
,8892677,peak blood levels,"The median trough and peak blood levels of SDZ PSC 833 ranged from 461/1134 ng/ml at 5 mg/kg/day to 821/2663 ng/ml at 15 mg/kg, respectively.","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [ml],1134,276,DB00541,Vincristine
,8892677,peak blood levels,"The median trough and peak blood levels of SDZ PSC 833 ranged from 461/1134 ng/ml at 5 mg/kg/day to 821/2663 ng/ml at 15 mg/kg, respectively.","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [ml],821,277,DB00541,Vincristine
,8892677,peak blood levels,"The median trough and peak blood levels of SDZ PSC 833 ranged from 461/1134 ng/ml at 5 mg/kg/day to 821/2663 ng/ml at 15 mg/kg, respectively.","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [ml],2663,278,DB00541,Vincristine
,8892677,plasma AUC 0-->96 h,"With addition of SDZ PSC 833 (5 mg/kg) the mean plasma AUC 0-->96 h of doxorubicin as compared with control patients treated with VAD increased from 779 to 1510 ng/ml/h (P=0.0071), while the doxorubicin clearance was reduced from 47.6 to 27.8 l/h/m2 (P=0.0002).","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [h·ml],77,279,DB00541,Vincristine
,8892677,clearance,"With addition of SDZ PSC 833 (5 mg/kg) the mean plasma AUC 0-->96 h of doxorubicin as compared with control patients treated with VAD increased from 779 to 1510 ng/ml/h (P=0.0071), while the doxorubicin clearance was reduced from 47.6 to 27.8 l/h/m2 (P=0.0002).","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[l] / [h·m2],47.6,280,DB00541,Vincristine
,16840188,overall response rate,"Best response included five CR, six PR, one SD and one PD with an overall response rate of 85% and complete response rate of 38%.","Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840188/),%,85,284,DB00541,Vincristine
,16840188,complete response rate,"Best response included five CR, six PR, one SD and one PD with an overall response rate of 85% and complete response rate of 38%.","Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840188/),%,38,285,DB00541,Vincristine
,19708032,MTD,"The MTD of VSLI was 2.25 mg/m(2) based on dose-limiting toxicities of grade 3 motor neuropathy, grade 4 seizure, and grade 4 hepatotoxicity in 1 patient each at the 2.4 mg/m(2) dose level.",Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19708032/),[mg] / [m(2],2.25,6901,DB00541,Vincristine
,19708032,CR rate,A complete response (CR) was achieved in 7 of 36 patients (19%) based on an intent-to-treat analysis; the CR rate was 29% for the 14 patients who underwent therapy as their first salvage attempt.,Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19708032/),,29,6902,DB00541,Vincristine
,20920295,AUC₀₋₇,"Mean AUC₀₋₇ (days) was 155.9 versus 152.4 mg*h/mL for Prolastin-C and Prolastin, respectively.",Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920295/),[h·mg] / [ml],155.9,10708,DB00541,Vincristine
,20920295,AUC₀₋₇,"Mean AUC₀₋₇ (days) was 155.9 versus 152.4 mg*h/mL for Prolastin-C and Prolastin, respectively.",Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920295/),[h·mg] / [ml],152.4,10709,DB00541,Vincristine
,21658147,clearance,"The median clearance, area under the curve and Cmax of vincristine was 482 mL/min/m(2) (range 132-698), 49.7 mcg/L.h (16.5-143.1) and 3.5 mcg/L (1.0-31.2), respectively.","Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21658147/),[min·ml] / [m(2],482,15054,DB00541,Vincristine
,21658147,area under the curve,"The median clearance, area under the curve and Cmax of vincristine was 482 mL/min/m(2) (range 132-698), 49.7 mcg/L.h (16.5-143.1) and 3.5 mcg/L (1.0-31.2), respectively.","Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21658147/),[mcg] / [h·l],49.7,15055,DB00541,Vincristine
,21658147,Cmax,"The median clearance, area under the curve and Cmax of vincristine was 482 mL/min/m(2) (range 132-698), 49.7 mcg/L.h (16.5-143.1) and 3.5 mcg/L (1.0-31.2), respectively.","Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21658147/),[mcg] / [l],3.5,15056,DB00541,Vincristine
,26875154,unbound cisplatin plasma concentrations,"Treatment of a child aged 2 weeks with a recommended cisplatin dose reduction for weight to 1.8 mg/kg resulted in achievement of unbound cisplatin plasma concentrations of 0.01-0.08 µg/mL, markedly lower than exposures previously reported in infants and older children.",Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26875154/),[μg] / [ml],0.01-0.08,17294,DB00541,Vincristine
,17579865,peak plasma level,Mean peak plasma level after intravenous etoposide was significantly higher compared to oral administration (16.3+/-3.7 vs. 12.0+/-4.2 microg/ml; P=0.015).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[μg] / [ml],16.3,19185,DB00541,Vincristine
,17579865,peak plasma level,Mean peak plasma level after intravenous etoposide was significantly higher compared to oral administration (16.3+/-3.7 vs. 12.0+/-4.2 microg/ml; P=0.015).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[μg] / [ml],12.0,19186,DB00541,Vincristine
,17579865,bioavailability,The mean bioavailability of oral etoposide was 58+/-15% with an interpatient variability of 26%.,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),%,58,19187,DB00541,Vincristine
,17579865,AUC,Mean AUC after a 100 mg/m2 intravenous and a 200 mg/m2 oral dose of etoposide were 74.0+/-18.3 and 84.9+/-29.6 microg h/ml (P=0.481).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[h·μg] / [ml],74.0,19188,DB00541,Vincristine
,17579865,AUC,Mean AUC after a 100 mg/m2 intravenous and a 200 mg/m2 oral dose of etoposide were 74.0+/-18.3 and 84.9+/-29.6 microg h/ml (P=0.481).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[h·μg] / [ml],84.9,19189,DB00541,Vincristine
,17579865,excretion,Urinary etoposide excretion as percentage of administered dose was 39.4+/-10.6% after intravenous infusion versus 35.4+/-9.4% after oral intake (P=0.422).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),%,39.4,19190,DB00541,Vincristine
,17579865,excretion,Urinary etoposide excretion as percentage of administered dose was 39.4+/-10.6% after intravenous infusion versus 35.4+/-9.4% after oral intake (P=0.422).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),%,35.4,19191,DB00541,Vincristine
,17579865,Renal clearance,Renal clearance was also very similar with intravenous and oral route (18.5+/-7.4 vs. 16.7+/-6.6 ml/min; P=0.546).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[ml] / [min],18.5,19192,DB00541,Vincristine
,17579865,Renal clearance,Renal clearance was also very similar with intravenous and oral route (18.5+/-7.4 vs. 16.7+/-6.6 ml/min; P=0.546).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[ml] / [min],16.7,19193,DB00541,Vincristine
,10850396,elimination half-life,The Rituximab elimination half-life of approximately 20 days accounts for the demonstrated accumulation of MAb in serum samples.,Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850396/),d,20,19743,DB00541,Vincristine
,7700168,volume of distribution at steady-state,"Estimated pharmacokinetic parameters were highly variable; mean (S.D.) volume of distribution at steady-state was 360 (176) L.m-2; total body clearance was 431 (238) ml.min-1.m-2, and elimination half-life was 823 (390) min.",Vincristine disposition in children with acute lymphoblastic leukemia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7700168/),[l] / [(m)^2],360,23189,DB00541,Vincristine
,7700168,total body clearance,"Estimated pharmacokinetic parameters were highly variable; mean (S.D.) volume of distribution at steady-state was 360 (176) L.m-2; total body clearance was 431 (238) ml.min-1.m-2, and elimination half-life was 823 (390) min.",Vincristine disposition in children with acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7700168/),[ml] / [(m)^2·min],431,23190,DB00541,Vincristine
,7700168,elimination half-life,"Estimated pharmacokinetic parameters were highly variable; mean (S.D.) volume of distribution at steady-state was 360 (176) L.m-2; total body clearance was 431 (238) ml.min-1.m-2, and elimination half-life was 823 (390) min.",Vincristine disposition in children with acute lymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7700168/),min,823,23191,DB00541,Vincristine
,21586299,plasma half-life,"Preventive lacosamide treatment (30 mg/kg subcutaneously b.i.d. for 17 days) was well tolerated, and pharmacokinetic analysis revealed a peak plasma concentration 2 h post-injection with a plasma half-life of approximately 3 h.",Lacosamide has protective disease modifying properties in experimental vincristine neuropathy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21586299/),h,3,26736,DB00541,Vincristine
,9421103,alpha,"The mean (SEM) values of alpha, beta, k12, k21, k10, Vc, Vss, AUC, total clearance, and mean residence time observed in Group-1 were 4.06 (0.96) hr(-1), 0.0395 (0.0068) hr(-1), 3.13 (0.79) hr(-1), 0.264 (0.052) hr(-1), 0.708 (0.19) hr(-1), 525 (156) l/m2, 1060 (163) l/m2, 1145 (234) microg x hr/l, 49.3 (8.5) l/hr x m2, and 26.8 (6.6) hours, respectively.",Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421103/),1/[hr],4.06,27469,DB00541,Vincristine
,9421103,mean residence time,"The mean (SEM) values of alpha, beta, k12, k21, k10, Vc, Vss, AUC, total clearance, and mean residence time observed in Group-1 were 4.06 (0.96) hr(-1), 0.0395 (0.0068) hr(-1), 3.13 (0.79) hr(-1), 0.264 (0.052) hr(-1), 0.708 (0.19) hr(-1), 525 (156) l/m2, 1060 (163) l/m2, 1145 (234) microg x hr/l, 49.3 (8.5) l/hr x m2, and 26.8 (6.6) hours, respectively.",Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421103/),[h·μg] / [l],1145,27470,DB00541,Vincristine
,9421103,mean residence time,"The mean (SEM) values of alpha, beta, k12, k21, k10, Vc, Vss, AUC, total clearance, and mean residence time observed in Group-1 were 4.06 (0.96) hr(-1), 0.0395 (0.0068) hr(-1), 3.13 (0.79) hr(-1), 0.264 (0.052) hr(-1), 0.708 (0.19) hr(-1), 525 (156) l/m2, 1060 (163) l/m2, 1145 (234) microg x hr/l, 49.3 (8.5) l/hr x m2, and 26.8 (6.6) hours, respectively.",Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421103/),[l] / [h·m2],49.3,27471,DB00541,Vincristine
,9421103,mean residence time,"The mean (SEM) values of alpha, beta, k12, k21, k10, Vc, Vss, AUC, total clearance, and mean residence time observed in Group-1 were 4.06 (0.96) hr(-1), 0.0395 (0.0068) hr(-1), 3.13 (0.79) hr(-1), 0.264 (0.052) hr(-1), 0.708 (0.19) hr(-1), 525 (156) l/m2, 1060 (163) l/m2, 1145 (234) microg x hr/l, 49.3 (8.5) l/hr x m2, and 26.8 (6.6) hours, respectively.",Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421103/),h,26.8,27472,DB00541,Vincristine
,28611009,circulation half-life,"Increase in PEG coverage prolonged nanoparticle circulation half-life up to ~20h in rats and ~10h in mice and decreased retention in liver, spleen and lungs.",Comprehensive study of the drug delivery properties of poly(l-lactide)-poly(ethylene glycol) nanoparticles in rats and tumor-bearing mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28611009/),h,20,30600,DB00541,Vincristine
,28611009,circulation half-life,"Increase in PEG coverage prolonged nanoparticle circulation half-life up to ~20h in rats and ~10h in mice and decreased retention in liver, spleen and lungs.",Comprehensive study of the drug delivery properties of poly(l-lactide)-poly(ethylene glycol) nanoparticles in rats and tumor-bearing mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28611009/),h,10,30601,DB00541,Vincristine
,16419071,progression-free survival,Median progression-free survival was 7 months with VAD alone and 4.9 months with valspodar (P = 0.50).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),month,7,32967,DB00541,Vincristine
,16419071,progression-free survival,Median progression-free survival was 7 months with VAD alone and 4.9 months with valspodar (P = 0.50).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),month,4.9,32968,DB00541,Vincristine
,16419071,Subjective response,Subjective response was 19% with VAD alone and 17% with valspodar (P = 1.0).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),,19,32969,DB00541,Vincristine
,16419071,survival,Median survival with VAD alone was 18.5 months and 15.3 with the addition of valspodar (P = 0.055).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),month,18.,32970,DB00541,Vincristine
,16419071,Toxicity,Toxicity of Grade 3 or greater was higher (P < 0.0001) in the valspodar arm (89%) compared with the VAD-alone arm (58%).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),%,89,32971,DB00541,Vincristine
,16419071,Toxicity,Toxicity of Grade 3 or greater was higher (P < 0.0001) in the valspodar arm (89%) compared with the VAD-alone arm (58%).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),%,58,32972,DB00541,Vincristine
,9523729,maximum observed concentration,"The mean maximum observed concentration values were significantly greater for patients receiving VSLI at 2.8 mg/m2 (2260 +/- 212 ng/ml, n = 2) than for those receiving 2.0 mg/m2 and 2.4 mg/m2 (891 +/- 671 ng/ml, n = 6; 679 +/- 634 ng/ml, n = 6, respectively).",Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523729/),[ng] / [ml],2260,34190,DB00541,Vincristine
,9523729,maximum observed concentration,"The mean maximum observed concentration values were significantly greater for patients receiving VSLI at 2.8 mg/m2 (2260 +/- 212 ng/ml, n = 2) than for those receiving 2.0 mg/m2 and 2.4 mg/m2 (891 +/- 671 ng/ml, n = 6; 679 +/- 634 ng/ml, n = 6, respectively).",Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523729/),[ng] / [ml],891,34191,DB00541,Vincristine
,9523729,maximum observed concentration,"The mean maximum observed concentration values were significantly greater for patients receiving VSLI at 2.8 mg/m2 (2260 +/- 212 ng/ml, n = 2) than for those receiving 2.0 mg/m2 and 2.4 mg/m2 (891 +/- 671 ng/ml, n = 6; 679 +/- 634 ng/ml, n = 6, respectively).",Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523729/),[ng] / [ml],679,34192,DB00541,Vincristine
,25520304,flow rate,"The analyte was extracted from urine samples using liquid-liquid extraction after addition of vinblastine (VBL, used as internal standard) and chromatographed on an Acquity UPLC HSS T3 column with a gradient mobile phase at a flow rate of 0.4 mL/min.",Validation of an UPLC-MS-MS Method for Quantitative Analysis of Vincristine in Human Urine After Intravenous Administration of Vincristine Sulfate Liposome Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25520304/),[ml] / [min],0.4,36607,DB00541,Vincristine
,9502163,Recovery,Recovery of VINC from plasma and VINC from plasma spiked with vincristine sulfate liposome injection ranged from 74.9-87.1%.,Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9502163/),%,74.9-87.1,37705,DB00541,Vincristine
,19184019,t (1/2),"Nanoliposome formulations of vincristine and vinblastine demonstrated similar pharmacokinetic profiles for the liposomal carrier, but increased clearance for liposome encapsulated vinblastine (t (1/2) = 9.7 h) relative to vincristine (t (1/2) = 18.5 h).",Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19184019/),h,9.7,39594,DB00541,Vincristine
,19184019,t (1/2),"Nanoliposome formulations of vincristine and vinblastine demonstrated similar pharmacokinetic profiles for the liposomal carrier, but increased clearance for liposome encapsulated vinblastine (t (1/2) = 9.7 h) relative to vincristine (t (1/2) = 18.5 h).",Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19184019/),h,18.5,39595,DB00541,Vincristine
,34080039,area under the concentration-time curve [AUC] ratio,"Extrapolation of the vincristine mechanistic PBPK model to other P-gp substrates further suggested DDI risk when ibrutinib (area under the concentration-time curve [AUC] ratio: 1.8), but not acalabrutinib (AUC ratio: 0.92), was given orally with venetoclax or digoxin.",Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34080039/),,1.8,41785,DB00541,Vincristine
,34080039,AUC ratio,"Extrapolation of the vincristine mechanistic PBPK model to other P-gp substrates further suggested DDI risk when ibrutinib (area under the concentration-time curve [AUC] ratio: 1.8), but not acalabrutinib (AUC ratio: 0.92), was given orally with venetoclax or digoxin.",Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34080039/),,0.92,41786,DB00541,Vincristine
,10348798,biliary excretion clearance,"One-tenth milligram per kilogram PSC 833 was sufficient to significantly reduce the biliary excretion clearance of DGX from 3.0 ml/min/kg to 0.5 ml/min/kg, whereas 3 mg/kg PSC 833 was needed to significantly reduce the biliary excretion clearance of VCR from 36 ml/min/kg to 9 ml/min/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),[ml] / [kg·min],3.0,44601,DB00541,Vincristine
,10348798,biliary excretion clearance,"One-tenth milligram per kilogram PSC 833 was sufficient to significantly reduce the biliary excretion clearance of DGX from 3.0 ml/min/kg to 0.5 ml/min/kg, whereas 3 mg/kg PSC 833 was needed to significantly reduce the biliary excretion clearance of VCR from 36 ml/min/kg to 9 ml/min/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),[ml] / [kg·min],0.5,44602,DB00541,Vincristine
,10348798,biliary excretion clearance,"One-tenth milligram per kilogram PSC 833 was sufficient to significantly reduce the biliary excretion clearance of DGX from 3.0 ml/min/kg to 0.5 ml/min/kg, whereas 3 mg/kg PSC 833 was needed to significantly reduce the biliary excretion clearance of VCR from 36 ml/min/kg to 9 ml/min/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),[ml] / [kg·min],36,44603,DB00541,Vincristine
,10348798,biliary excretion clearance,"One-tenth milligram per kilogram PSC 833 was sufficient to significantly reduce the biliary excretion clearance of DGX from 3.0 ml/min/kg to 0.5 ml/min/kg, whereas 3 mg/kg PSC 833 was needed to significantly reduce the biliary excretion clearance of VCR from 36 ml/min/kg to 9 ml/min/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),[ml] / [kg·min],9,44604,DB00541,Vincristine
,10348798,tissue-to-plasma,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,0.34,44605,DB00541,Vincristine
,10348798,tissue-to-plasma,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.64,44606,DB00541,Vincristine
,10348798,tissue-to-plasma,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.07,44607,DB00541,Vincristine
,10348798,tissue-to-plasma,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.37,44608,DB00541,Vincristine
,10348798,concentration ratio,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,0.34,44609,DB00541,Vincristine
,10348798,concentration ratio,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.64,44610,DB00541,Vincristine
,10348798,concentration ratio,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.07,44611,DB00541,Vincristine
,10348798,concentration ratio,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.37,44612,DB00541,Vincristine
,15371983,elimination half-life,"When haplotypes were assigned, haplotype 1/1 carriers (3435C/2677G) showed a longer elimination half-life than noncarriers (1156 versus 805 minutes, P =.038).",Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371983/),min,1156,44763,DB00541,Vincristine
,15371983,elimination half-life,"When haplotypes were assigned, haplotype 1/1 carriers (3435C/2677G) showed a longer elimination half-life than noncarriers (1156 versus 805 minutes, P =.038).",Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371983/),min,805,44764,DB00541,Vincristine
,15371983,elimination half-life,"In contrast, haplotype 1/2 carriers (3435T/2677G) had a shorter elimination half-life than noncarriers (805 versus 1180 minutes, P =.044).",Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371983/),min,805,44765,DB00541,Vincristine
,15371983,elimination half-life,"In contrast, haplotype 1/2 carriers (3435T/2677G) had a shorter elimination half-life than noncarriers (805 versus 1180 minutes, P =.044).",Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371983/),min,1180,44766,DB00541,Vincristine
,18537965,total plasma clearance,"The median total plasma clearance was 429 and 331 ml/min per m(2) and the area under the plasma concentration-time curve (AUC) was 4.49 and 5.40 mg/l x min in relapse and non-relapse patients, respectively (not significant).",Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18537965/),[min·ml] / [m(2],429,45156,DB00541,Vincristine
,18537965,total plasma clearance,"The median total plasma clearance was 429 and 331 ml/min per m(2) and the area under the plasma concentration-time curve (AUC) was 4.49 and 5.40 mg/l x min in relapse and non-relapse patients, respectively (not significant).",Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18537965/),[min·ml] / [m(2],331,45157,DB00541,Vincristine
,18537965,area under the plasma concentration-time curve (AUC),"The median total plasma clearance was 429 and 331 ml/min per m(2) and the area under the plasma concentration-time curve (AUC) was 4.49 and 5.40 mg/l x min in relapse and non-relapse patients, respectively (not significant).",Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18537965/),[mg] / [l·min],4.49,45158,DB00541,Vincristine
,18537965,area under the plasma concentration-time curve (AUC),"The median total plasma clearance was 429 and 331 ml/min per m(2) and the area under the plasma concentration-time curve (AUC) was 4.49 and 5.40 mg/l x min in relapse and non-relapse patients, respectively (not significant).",Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18537965/),[mg] / [l·min],5.40,45159,DB00541,Vincristine
,11504822,half-life,"Vincristine elimination from the circulation after injection of conventional, aqueous formulated vincristine (C-VINC) was characterized by a short half-life (1.36 h), low plasma area under the plasma concentration-time curve (AUC) (0.59 microg x h/ml), and large volume of distribution (145 ml).",Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504822/),h,1.36,47492,DB00541,Vincristine
,11504822,plasma area under the plasma concentration-time curve (AUC),"Vincristine elimination from the circulation after injection of conventional, aqueous formulated vincristine (C-VINC) was characterized by a short half-life (1.36 h), low plasma area under the plasma concentration-time curve (AUC) (0.59 microg x h/ml), and large volume of distribution (145 ml).",Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504822/),[h·μg] / [ml],0.59,47493,DB00541,Vincristine
,11504822,volume of distribution,"Vincristine elimination from the circulation after injection of conventional, aqueous formulated vincristine (C-VINC) was characterized by a short half-life (1.36 h), low plasma area under the plasma concentration-time curve (AUC) (0.59 microg x h/ml), and large volume of distribution (145 ml).",Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504822/),ml,145,47494,DB00541,Vincristine
,11504822,half-life,"Total drug elimination from the circulation after liposomal vincristine injection using SM/Chol liposomes was characterized by a prolonged half-life (6.6 h), increased plasma AUC (213 microg x h/ml) and small volume of distribution (2.0 ml).",Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504822/),h,6.6,47495,DB00541,Vincristine
,11504822,plasma AUC,"Total drug elimination from the circulation after liposomal vincristine injection using SM/Chol liposomes was characterized by a prolonged half-life (6.6 h), increased plasma AUC (213 microg x h/ml) and small volume of distribution (2.0 ml).",Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504822/),[h·μg] / [ml],213,47496,DB00541,Vincristine
,11504822,volume of distribution,"Total drug elimination from the circulation after liposomal vincristine injection using SM/Chol liposomes was characterized by a prolonged half-life (6.6 h), increased plasma AUC (213 microg x h/ml) and small volume of distribution (2.0 ml).",Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504822/),ml,2.0,47497,DB00541,Vincristine
,11504822,Plasma concentrations,Plasma concentrations of free drug remained between 0.025 and 0.05 microg/ml over 4 h of postinjection for both liposomal formulations.,Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504822/),[μg] / [ml],0.025 and 0.05,47498,DB00541,Vincristine
,29115708,maximum dose,Patients received IV VCR 2 mg/m2 /dose with a maximum dose of 2.5 mg as part of standard treatment protocols.,CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29115708/),mg,2.5,54901,DB00541,Vincristine
,29115708,dose,"CYP3A5 low-expresser genotype subjects had a significantly higher dose and body surface area normalized area under the curve than CYP3A5 high-expresser genotype subjects (0.28 ± 0.15 hr·m2 /l vs. 0.15 ± 0.011 hr·m2 /l, P = 0.027).",CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29115708/),[h·m2] / [l],0.28,54902,DB00541,Vincristine
,29115708,body surface area normalized area under the curve,"CYP3A5 low-expresser genotype subjects had a significantly higher dose and body surface area normalized area under the curve than CYP3A5 high-expresser genotype subjects (0.28 ± 0.15 hr·m2 /l vs. 0.15 ± 0.011 hr·m2 /l, P = 0.027).",CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29115708/),[h·m2] / [l],0.15,54903,DB00541,Vincristine
,6891324,half-lives,"The three successive half-lives presented little individual variations and were 4.75 min, 0.822 hr and 18.9 hr.",Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891324/),min,4.75,55225,DB00541,Vincristine
,6891324,half-lives,"The three successive half-lives presented little individual variations and were 4.75 min, 0.822 hr and 18.9 hr.",Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891324/),h,0.822,55226,DB00541,Vincristine
,6891324,half-lives,"The three successive half-lives presented little individual variations and were 4.75 min, 0.822 hr and 18.9 hr.",Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891324/),h,18.9,55227,DB00541,Vincristine
,6891324,total plasma clearance,The total plasma clearance of the parent drug ranged from 28.3 to 98.7 1/hr.,Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891324/),[1] / [h],28.3 to 98.7,55228,DB00541,Vincristine
,26711181,overall,"The overall and complete response rates were 68% and 37%, respectively.",Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26711181/),%,68,56026,DB00541,Vincristine
,26711181,complete response rates,"The overall and complete response rates were 68% and 37%, respectively.",Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26711181/),%,37,56027,DB00541,Vincristine
,26711181,trough levels,"Highest day 1 alemtuzumab trough levels were achieved at 60 mg (1973 ng/mL), but with significant inter- and intradose variability.",Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26711181/),[ng] / [ml],1973,56028,DB00541,Vincristine
,9661014,half-life,"The concentration of ITZ in liver tissue declined in parallel with the plasma ITZ concentration until 24 h after intravenous injection of the drug (half-life, 5 h); however, the ITZ in brain tissue rapidly disappeared (half-life, 0.4 h).",P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661014/),h,5,56069,DB00541,Vincristine
,9661014,half-life,"The concentration of ITZ in liver tissue declined in parallel with the plasma ITZ concentration until 24 h after intravenous injection of the drug (half-life, 5 h); however, the ITZ in brain tissue rapidly disappeared (half-life, 0.4 h).",P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661014/),h,0.4,56070,DB00541,Vincristine
,30210349,maximum concentration (Cmax,"VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (Cmax, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC0-Inf, 222.1 ng/mL h), markedly decreased distribution volume (Vz, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower Cmax (26.6 ng/mL) and AUC0-Inf (95.1 ng/mL h), larger Vz (688.8 L) and CL (22.1 L/h) for VSI.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),[ng] / [ml],86.6,57819,DB00541,Vincristine
,30210349,distribution volume (Vz,"VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (Cmax, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC0-Inf, 222.1 ng/mL h), markedly decreased distribution volume (Vz, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower Cmax (26.6 ng/mL) and AUC0-Inf (95.1 ng/mL h), larger Vz (688.8 L) and CL (22.1 L/h) for VSI.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),l,224.1,57820,DB00541,Vincristine
,30210349,plasma clearance (CL,"VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (Cmax, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC0-Inf, 222.1 ng/mL h), markedly decreased distribution volume (Vz, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower Cmax (26.6 ng/mL) and AUC0-Inf (95.1 ng/mL h), larger Vz (688.8 L) and CL (22.1 L/h) for VSI.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),[l] / [h],8.9,57821,DB00541,Vincristine
,30210349,Cmax,"VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (Cmax, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC0-Inf, 222.1 ng/mL h), markedly decreased distribution volume (Vz, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower Cmax (26.6 ng/mL) and AUC0-Inf (95.1 ng/mL h), larger Vz (688.8 L) and CL (22.1 L/h) for VSI.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),[ng] / [ml],26.6,57822,DB00541,Vincristine
,30210349,AUC0-Inf,"VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (Cmax, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC0-Inf, 222.1 ng/mL h), markedly decreased distribution volume (Vz, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower Cmax (26.6 ng/mL) and AUC0-Inf (95.1 ng/mL h), larger Vz (688.8 L) and CL (22.1 L/h) for VSI.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),[ng] / [h·ml],95.1,57823,DB00541,Vincristine
,30210349,Vz,"VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (Cmax, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC0-Inf, 222.1 ng/mL h), markedly decreased distribution volume (Vz, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower Cmax (26.6 ng/mL) and AUC0-Inf (95.1 ng/mL h), larger Vz (688.8 L) and CL (22.1 L/h) for VSI.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),l,688.8,57824,DB00541,Vincristine
,30210349,CL,"VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (Cmax, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC0-Inf, 222.1 ng/mL h), markedly decreased distribution volume (Vz, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower Cmax (26.6 ng/mL) and AUC0-Inf (95.1 ng/mL h), larger Vz (688.8 L) and CL (22.1 L/h) for VSI.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),[l] / [h],22.1,57825,DB00541,Vincristine
,30210349,Cmax,The small proportion of F-VCR following infusion of VSLI in circulation was reflected by very low Cmax (1.8 ng/mL) and AUC0-Inf (50.5 ng/mL h).,Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),[ng] / [ml],1.8,57826,DB00541,Vincristine
,30210349,AUC0-Inf,The small proportion of F-VCR following infusion of VSLI in circulation was reflected by very low Cmax (1.8 ng/mL) and AUC0-Inf (50.5 ng/mL h).,Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),[ng] / [h·ml],50.5,57827,DB00541,Vincristine
,30210349,elimination percentage,"The elimination percentage of 40-21-14% for VSI changed to 6.2-24-39% for VSLI at intervals of 0-5, 5-13 and 13-25 h, respectively.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),%,40-21-14,57828,DB00541,Vincristine
,30210349,elimination percentage,"The elimination percentage of 40-21-14% for VSI changed to 6.2-24-39% for VSLI at intervals of 0-5, 5-13 and 13-25 h, respectively.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),%,6,57829,DB00541,Vincristine
,25537545,Area under the concentration time curve (AUC48-∝),"Area under the concentration time curve (AUC48-∝) of MTX significantly increased in variant group [(23.18±19.91) vs.(5.66±2.01) h·µmol/L] (t=4.025, P=0.001).",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[h·μM] / [l],23.18,57930,DB00541,Vincristine
,25537545,Area under the concentration time curve (AUC48-∝),"Area under the concentration time curve (AUC48-∝) of MTX significantly increased in variant group [(23.18±19.91) vs.(5.66±2.01) h·µmol/L] (t=4.025, P=0.001).",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[h·μM] / [l],5.66,57931,DB00541,Vincristine
>,25537545,Time above the,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[μM] / [l],0.1,57932,DB00541,Vincristine
,25537545,Time above the,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,95.3,57933,DB00541,Vincristine
,25537545,Time above the,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,67.1,57934,DB00541,Vincristine
>,25537545,safety threshold (,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[μM] / [l],0.1,57935,DB00541,Vincristine
,25537545,safety threshold (,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,95.3,57936,DB00541,Vincristine
,25537545,safety threshold (,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,67.1,57937,DB00541,Vincristine
>,25537545,TC,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[μM] / [l],0.1,57938,DB00541,Vincristine
,25537545,TC,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,95.3,57939,DB00541,Vincristine
,25537545,TC,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,67.1,57940,DB00541,Vincristine
,25537545,Hospital stay,"Hospital stay of variant group was significantly longer than that of wild-type [(4.95±1.43) vs. (4.05±0.22) d, t=2.881, P=0.009].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),d,4.95,57941,DB00541,Vincristine
,25537545,Hospital stay,"Hospital stay of variant group was significantly longer than that of wild-type [(4.95±1.43) vs. (4.05±0.22) d, t=2.881, P=0.009].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),d,4.05,57942,DB00541,Vincristine
,9808549,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) of methotrexate ranged from 0.63 to 12 micromol*h/L, and the AUC of mercaptopurine ranged from 0.11 to 8 micromol*h/L.",Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808549/),[h·μM] / [l],0.63 to 12,59168,DB00541,Vincristine
,9808549,AUC,"The area under the plasma concentration-time curve (AUC) of methotrexate ranged from 0.63 to 12 micromol*h/L, and the AUC of mercaptopurine ranged from 0.11 to 8 micromol*h/L.",Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808549/),[h·μM] / [l],0.11 to 8,59169,DB00541,Vincristine
,19834427,clearance,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),[l] / [h],23.1,59323,DB00541,Vincristine
,19834427,central,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,35.4,59324,DB00541,Vincristine
,19834427,peripheral volume of distribution,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,35.4,59325,DB00541,Vincristine
,19834427,peripheral volume of distribution,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,1090,59326,DB00541,Vincristine
,19834427,intercompartmental clearance,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,27.3,59327,DB00541,Vincristine
,19834427,mean transit time (tau),"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),d,3.8,59328,DB00541,Vincristine
,19834427,tau,"When patients had an early decrease in bilirubin at day 7, tau increased to 28.2 days.",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),d,28.2,59329,DB00541,Vincristine
,8722343,clearance rate,The mean VP-16 clearance rate was 17.3 ml/min/m2 with continuous infusion.,Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722343/),[ml] / [m2·min],17.3,62274,DB00541,Vincristine
,8722343,steady-state plasma concentration,"A mean steady-state plasma concentration of 24.2 micrograms/ml (s.d. = 2) and 28.3 micrograms/ml (s.d. = 1.9) was achieved at the 1800 mg/ml and 2100 mg/m2 dose levels, respectively, GI toxicity is dose limiting when VP-16 at 2400 mg/m2/72 h, is associated with HDM.",Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722343/),[μg] / [ml],24.2,62275,DB00541,Vincristine
,8722343,steady-state plasma concentration,"A mean steady-state plasma concentration of 24.2 micrograms/ml (s.d. = 2) and 28.3 micrograms/ml (s.d. = 1.9) was achieved at the 1800 mg/ml and 2100 mg/m2 dose levels, respectively, GI toxicity is dose limiting when VP-16 at 2400 mg/m2/72 h, is associated with HDM.",Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722343/),[μg] / [ml],28.3,62276,DB00541,Vincristine
,7973765,terminal phase half-life,"There is a prolonged terminal phase due to relatively slow efflux of the drug from peripheral compartments, which results in a long terminal phase half-life, with average values ranging from 27.7 to 43.6 hours.",The clinical pharmacokinetics of vinorelbine (Navelbine). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7973765/),h,27.7 to 43.6,62420,DB00541,Vincristine
,7973765,absolute bioavailability,The absolute bioavailability of vinorelbine from this dosage form was 27% when intravenous doses of 30 mg/m2 were compared with oral doses of 100 mg/m2.,The clinical pharmacokinetics of vinorelbine (Navelbine). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7973765/),%,27,62421,DB00541,Vincristine
,7636539,MTD,"The MTD of dexverapamil was 150 mg/m2 every 4 hours (900 mg/m2/d), and hypotension was the principal dose-limiting toxicity.",Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636539/),[mg] / [m2],150,64149,DB00541,Vincristine
,12084857,total body clearance,"In this group of children pharmacokinetic factors were highly variable: median (25th and 75th percentiles) total body clearance, 228 (128-360) mL.min(-1).",Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12084857/),[ml] / [min],228,65835,DB00541,Vincristine
,12084857,elimination half-life,"m(-2); elimination half-life, 1001 (737-1325) min; apparent volume of distribution at steady state 262 (158-469) L/m(2).",Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12084857/),min,1001,65836,DB00541,Vincristine
,12084857,apparent volume of distribution at steady state,"m(-2); elimination half-life, 1001 (737-1325) min; apparent volume of distribution at steady state 262 (158-469) L/m(2).",Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12084857/),[l] / [m(2],262,65837,DB00541,Vincristine
,12084857,clearance,"Vincristine clearance was substantially slower than has been reported previously for children receiving vincristine in combination with steroids as part of combination chemotherapy (median clearance, 228 mL.min(-1).",Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12084857/),[ml] / [min],228,65838,DB00541,Vincristine
,12084857,clearance,"m(-2) versus mean clearance, 381 and 482 mL. min(-1).",Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12084857/),[ml] / [min],381,65839,DB00541,Vincristine
,12084857,clearance,"m(-2) versus mean clearance, 381 and 482 mL. min(-1).",Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12084857/),[ml] / [min],482,65840,DB00541,Vincristine
,2088769,terminal half-lives,"The average terminal half-lives of VLB and VCR were 14.3 h and 7.5 h, respectively.",In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. Vinblastine and vincristine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088769/),h,14.3,66564,DB00541,Vincristine
,2088769,terminal half-lives,"The average terminal half-lives of VLB and VCR were 14.3 h and 7.5 h, respectively.",In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. Vinblastine and vincristine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088769/),h,7.5,66565,DB00541,Vincristine
,2088769,systemic clearance,"The systemic clearance and apparent distribution volume for VLB, respectively 1.49 l/h/kg and 11.46 l/kg, were significantly greater than those of VCR, 0.12 l/h/kg and 0.41 l/kg.",In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. Vinblastine and vincristine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088769/),[l] / [h·kg],1.49,66566,DB00541,Vincristine
,2088769,systemic clearance,"The systemic clearance and apparent distribution volume for VLB, respectively 1.49 l/h/kg and 11.46 l/kg, were significantly greater than those of VCR, 0.12 l/h/kg and 0.41 l/kg.",In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. Vinblastine and vincristine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088769/),[l] / [h·kg],0.12,66567,DB00541,Vincristine
,2088769,apparent distribution volume,"The systemic clearance and apparent distribution volume for VLB, respectively 1.49 l/h/kg and 11.46 l/kg, were significantly greater than those of VCR, 0.12 l/h/kg and 0.41 l/kg.",In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. Vinblastine and vincristine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088769/),[l] / [kg],11.46,66568,DB00541,Vincristine
,2088769,apparent distribution volume,"The systemic clearance and apparent distribution volume for VLB, respectively 1.49 l/h/kg and 11.46 l/kg, were significantly greater than those of VCR, 0.12 l/h/kg and 0.41 l/kg.",In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. Vinblastine and vincristine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088769/),[l] / [kg],0.41,66569,DB00541,Vincristine
,2088769,drug accumulation site,The highest drug accumulation site was the intestine (122.0 ng/g wet tissue at 24 h).,In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. Vinblastine and vincristine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088769/),[ng] / [g],122.0,66570,DB00541,Vincristine
,28239897,specific clearance,"The data were best described by a two-compartment model comprising linear nonspecific clearance of 0.252 [95% confidence interval (CI): 0.227-0.279] l day-1 and time-varying specific clearance of 0.278 (95% CI: 0.181-0.390) l day-1 , corresponding to target-mediated drug disposition of rituximab.",Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28239897/),[l] / [d],0.278,68234,DB00541,Vincristine
,28239897,Rate constant of specific clearance decay,"Rate constant of specific clearance decay was 0.143 day-1 (95% CI: 0.0478-0.418) in patients with no disease progression, while in patients with disease progression it was 82.2% lower (95% CI: 33.4-95.0).",Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28239897/),1/[d],0.143,68235,DB00541,Vincristine
,8406379,peak plasma levels,The plasma pharmacokinetics were described by a one-compartment open model with peak plasma levels of 6.9 +/- 2.5 micrograms/ml.,Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8406379/),[μg] / [ml],6.9,69689,DB00541,Vincristine
,8406379,relative oral bioavailability,Mean relative oral bioavailability was generally high (91 +/- 27 per cent).,Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8406379/),%,91,69690,DB00541,Vincristine
,31099166,IC50 concentration,"In vitro, the IC50 concentration of entinostat ranged from 280 to 1300 nM.",Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31099166/),nM,280 to 1300,72304,DB00541,Vincristine
,31099166,Cmax,"Pharmacokinetic studies showed the average Cmax was 569.4 ng/mL (1.51 μM) with Tmax at 15 minutes, and total exposure (AUC0-12 h ) was 435.6 h × ng/mL.",Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31099166/),[ng] / [ml],569.4,72305,DB00541,Vincristine
,31099166,Cmax,"Pharmacokinetic studies showed the average Cmax was 569.4 ng/mL (1.51 μM) with Tmax at 15 minutes, and total exposure (AUC0-12 h ) was 435.6 h × ng/mL.",Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31099166/),μM,1.51,72306,DB00541,Vincristine
,31099166,Tmax,"Pharmacokinetic studies showed the average Cmax was 569.4 ng/mL (1.51 μM) with Tmax at 15 minutes, and total exposure (AUC0-12 h ) was 435.6 h × ng/mL.",Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31099166/),min,15,72307,DB00541,Vincristine
,31099166,total exposure (AUC0-12 h ),"Pharmacokinetic studies showed the average Cmax was 569.4 ng/mL (1.51 μM) with Tmax at 15 minutes, and total exposure (AUC0-12 h ) was 435.6 h × ng/mL.",Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31099166/),[h·ng] / [ml],435.6,72308,DB00541,Vincristine
,7260915,half-lives,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,1.9,74807,DB00541,Vincristine
,7260915,half-lives,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,19.2,74808,DB00541,Vincristine
,7260915,half-lives,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,1359,74809,DB00541,Vincristine
,7260915,half-lives,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),h,22.6,74810,DB00541,Vincristine
,7260915,beta,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,1.9,74811,DB00541,Vincristine
,7260915,beta,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,19.2,74812,DB00541,Vincristine
,7260915,beta,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,1359,74813,DB00541,Vincristine
,7260915,beta,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),h,22.6,74814,DB00541,Vincristine
,7260915,gamma,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,1.9,74815,DB00541,Vincristine
,7260915,gamma,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,19.2,74816,DB00541,Vincristine
,7260915,gamma,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,1359,74817,DB00541,Vincristine
,7260915,gamma,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),h,22.6,74818,DB00541,Vincristine
,7260915,apparent volume of the central compartment,"The apparent volume of the central compartment and the volume of distribution at steady state (Vdss) per 1.73 sq m body surface area were 4.1 and 167.6 liters, respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),l,4.1,74819,DB00541,Vincristine
,7260915,volume of distribution at steady state (Vdss),"The apparent volume of the central compartment and the volume of distribution at steady state (Vdss) per 1.73 sq m body surface area were 4.1 and 167.6 liters, respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),l,4.1,74820,DB00541,Vincristine
,7260915,volume of distribution at steady state (Vdss),"The apparent volume of the central compartment and the volume of distribution at steady state (Vdss) per 1.73 sq m body surface area were 4.1 and 167.6 liters, respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),l,167.6,74821,DB00541,Vincristine
,7260915,plasma clearance,"The plasma clearance was 141.9 ml/min/1.73 sq m, and the area under the concentration X time curve from 0 to infinity (AUC0 infinity) for 2 mg vincristine was 21,689 nM.min.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),[ml] / [1.73·m·min·sq],141.9,74822,DB00541,Vincristine
,7260915,area under the concentration X time curve from 0 to infinity (AUC0 infinity),"The plasma clearance was 141.9 ml/min/1.73 sq m, and the area under the concentration X time curve from 0 to infinity (AUC0 infinity) for 2 mg vincristine was 21,689 nM.min.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min·nM,"21,689",74823,DB00541,Vincristine
,902455,half-life t1/2,"Clearance of radioactivity from the blood was triphasic with half-life t1/2 values of 0.85, 7.4, and 164 min.",The pharmacokinetics of [3H]-vincristine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902455/),min,0.85,76758,DB00541,Vincristine
,902455,half-life t1/2,"Clearance of radioactivity from the blood was triphasic with half-life t1/2 values of 0.85, 7.4, and 164 min.",The pharmacokinetics of [3H]-vincristine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902455/),min,7.4,76759,DB00541,Vincristine
,902455,half-life t1/2,"Clearance of radioactivity from the blood was triphasic with half-life t1/2 values of 0.85, 7.4, and 164 min.",The pharmacokinetics of [3H]-vincristine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902455/),min,164,76760,DB00541,Vincristine
,11304769,complete response rates,"The complete response rates were 30% and 48% among patients who received mCHOP and full-dose CHOP combined with HAART, respectively.",Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304769/),%,30,86057,DB00541,Vincristine
,11304769,complete response rates,"The complete response rates were 30% and 48% among patients who received mCHOP and full-dose CHOP combined with HAART, respectively.",Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304769/),%,48,86058,DB00541,Vincristine
,20382523,logClearance,"Mean vincristine logClearance was lower in Malawian as compared to UK patients (2.2 versus 2.6 ml/min, p=0.001).",Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382523/),[ml] / [min],2.2,86488,DB00541,Vincristine
,20382523,logClearance,"Mean vincristine logClearance was lower in Malawian as compared to UK patients (2.2 versus 2.6 ml/min, p=0.001).",Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382523/),[ml] / [min],2.6,86489,DB00541,Vincristine
,20382523,logAUC,"Mean logAUC values were higher in Malawian than in UK patients (3.8 versus 3.5 microg/mlmin, p=0.003).",Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382523/),[μg] / [mlmin],3.8,86490,DB00541,Vincristine
,20382523,logAUC,"Mean logAUC values were higher in Malawian than in UK patients (3.8 versus 3.5 microg/mlmin, p=0.003).",Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382523/),[μg] / [mlmin],3.5,86491,DB00541,Vincristine
,32737470,minimum optimal C1-trough,"The first cycle trough concentration (C1-trough) of rituximab was a significant independent risk factor for achieving CR in matched-pair logistic regression analysis, rather than the concentrations in later cycles; the recommendatory minimum optimal C1-trough was 13.60 μg/mL.",Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737470/),[μg] / [ml],13.60,88213,DB00541,Vincristine
,32737470,C1-trough,"Patients with grade 1/2 had significantly lower C1-trough compared with grade 3 (12.21 μg/mL vs. 23.45 μg/mL, P < 0.001), only 30% patients with grade 1/2 could reach 13.60 μg/mL, compared with 91.67% in patients with grade 3, which was in accord with its unsatisfactory CR rates (43.33% vs. 76.32%).",Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737470/),[μg] / [ml],12.21,88214,DB00541,Vincristine
,32737470,C1-trough,"Patients with grade 1/2 had significantly lower C1-trough compared with grade 3 (12.21 μg/mL vs. 23.45 μg/mL, P < 0.001), only 30% patients with grade 1/2 could reach 13.60 μg/mL, compared with 91.67% in patients with grade 3, which was in accord with its unsatisfactory CR rates (43.33% vs. 76.32%).",Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737470/),[μg] / [ml],23.45,88215,DB00541,Vincristine
,7710633,absolute bioavailability,"Cinchonine demonstrates a greater absolute bioavailability than quinine (44% versus 30%, respectively).",Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710633/),%,44,91127,DB00541,Vincristine
,7710633,absolute bioavailability,"Cinchonine demonstrates a greater absolute bioavailability than quinine (44% versus 30%, respectively).",Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710633/),%,30,91128,DB00541,Vincristine
,8826613,peak plasma concentrations (Cmax),Pharmacokinetic evaluations performed i.v. at the highest non-toxic dosage in mice bearing P03 tumors revealed CPT-11 peak plasma concentrations (Cmax) of 8.9 micrograms/ml and a terminal half-life of 0.6 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),[μg] / [ml],8.9,96648,DB00541,Vincristine
,8826613,terminal half-life,Pharmacokinetic evaluations performed i.v. at the highest non-toxic dosage in mice bearing P03 tumors revealed CPT-11 peak plasma concentrations (Cmax) of 8.9 micrograms/ml and a terminal half-life of 0.6 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,0.6,96649,DB00541,Vincristine
,8826613,Cmax,The metabolite SN-38 plasma concentrations presented a Cmax of 1.6 micrograms/ml and a terminal half-life of 7.4 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),[μg] / [ml],1.6,96650,DB00541,Vincristine
,8826613,terminal half-life,The metabolite SN-38 plasma concentrations presented a Cmax of 1.6 micrograms/ml and a terminal half-life of 7.4 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,7.4,96651,DB00541,Vincristine
,8826613,half-life,"Although the CPT-11 tumor levels were similar to the plasma concentrations for early time points, drug levels decreased more slowly in the tumor compared to plasma (half-life, 5.0 h).",Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,5.0,96652,DB00541,Vincristine
,8826613,half-life,SN-38 tumor levels reached concentrations in the range of 0.32-0.34 micrograms/g and decayed with a half-life of 6.9 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,6.9,96653,DB00541,Vincristine
above,8402633,tissue level/blood level ratio,"After i.v. administration to mice, GF120918 penetrates thoroughly various organs that have a tissue level/blood level ratio above 10.","In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402633/),,10,98460,DB00541,Vincristine
,8402633,half-time,It is eliminated from organs and blood with a half-time of approximately 2.7 h.,"In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402633/),h,2.7,98461,DB00541,Vincristine
,19920107,apparent clearance,Pegfilgrastim apparent clearance (11 mL/h/kg) was similar to that reported in adults.,Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19920107/),[ml] / [h·kg],11,98475,DB00541,Vincristine
,25403207,complete response (CR)/unconfirmed CR rate,"The complete response (CR)/unconfirmed CR rate was 85% in 189 evaluable patients, 90% for 90 good-prognosis patients (International Prognostic Index [IPI], 1 or 2), and 81% for 99 poor-prognosis patients (IPI, 3 to 5); 3-year event-free survival (EFS) was 71%, 75%, and 67%, respectively; and 3-year overall survival (OS) was 84%, 88%, and 80%, respectively, with no differences between men and women.",Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403207/),%,85,99063,DB00541,Vincristine
,25403207,complete response (CR)/unconfirmed CR rate,"The complete response (CR)/unconfirmed CR rate was 85% in 189 evaluable patients, 90% for 90 good-prognosis patients (International Prognostic Index [IPI], 1 or 2), and 81% for 99 poor-prognosis patients (IPI, 3 to 5); 3-year event-free survival (EFS) was 71%, 75%, and 67%, respectively; and 3-year overall survival (OS) was 84%, 88%, and 80%, respectively, with no differences between men and women.",Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403207/),%,90,99064,DB00541,Vincristine
,25403207,complete response (CR)/unconfirmed CR rate,"The complete response (CR)/unconfirmed CR rate was 85% in 189 evaluable patients, 90% for 90 good-prognosis patients (International Prognostic Index [IPI], 1 or 2), and 81% for 99 poor-prognosis patients (IPI, 3 to 5); 3-year event-free survival (EFS) was 71%, 75%, and 67%, respectively; and 3-year overall survival (OS) was 84%, 88%, and 80%, respectively, with no differences between men and women.",Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403207/),%,81,99065,DB00541,Vincristine
,18512312,complete remission (CR) rates,"The complete remission (CR) rates were 84.6% and 89.4%, total response rates were 92.3% and 93.9% (P < 0.05, respectively), and the incidence of adverse effects was 95.6% and 98.5% (P > 0.05) in the VDPAP and VDLP group, respectively.",[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18512312/),%,84.6,104383,DB00541,Vincristine
,18512312,complete remission (CR) rates,"The complete remission (CR) rates were 84.6% and 89.4%, total response rates were 92.3% and 93.9% (P < 0.05, respectively), and the incidence of adverse effects was 95.6% and 98.5% (P > 0.05) in the VDPAP and VDLP group, respectively.",[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18512312/),%,89.4,104384,DB00541,Vincristine
,18512312,total response rates,"The complete remission (CR) rates were 84.6% and 89.4%, total response rates were 92.3% and 93.9% (P < 0.05, respectively), and the incidence of adverse effects was 95.6% and 98.5% (P > 0.05) in the VDPAP and VDLP group, respectively.",[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18512312/),%,92.3,104385,DB00541,Vincristine
,18512312,total response rates,"The complete remission (CR) rates were 84.6% and 89.4%, total response rates were 92.3% and 93.9% (P < 0.05, respectively), and the incidence of adverse effects was 95.6% and 98.5% (P > 0.05) in the VDPAP and VDLP group, respectively.",[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18512312/),%,93.9,104386,DB00541,Vincristine
,18512312,half-life,"Pharmacokinetics showed that the half-life of PEG-Asp was (170 +/- 45) hours [about (7 +/- 2) days], the serum PEG-Asp activity levels > 0.1 IU/ml throughout induction.",[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18512312/),h,170,104387,DB00541,Vincristine
,18512312,half-life,"Pharmacokinetics showed that the half-life of PEG-Asp was (170 +/- 45) hours [about (7 +/- 2) days], the serum PEG-Asp activity levels > 0.1 IU/ml throughout induction.",[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18512312/),d,7,104388,DB00541,Vincristine
,17321495,half-time for LN clearance (Tc(1/2)),"For example, the half-time for LN clearance (Tc(1/2)) at a low lipid dose (15 micromol lipid/kg, corresponding to 8 mg lipid/kg body weight) in mice was 3.8 h for ESM/Chol LN compared to 6 h for DHSM/Chol LN.",Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17321495/),h,3.8,104521,DB00541,Vincristine
,17321495,half-time for LN clearance (Tc(1/2)),"For example, the half-time for LN clearance (Tc(1/2)) at a low lipid dose (15 micromol lipid/kg, corresponding to 8 mg lipid/kg body weight) in mice was 3.8 h for ESM/Chol LN compared to 6 h for DHSM/Chol LN.",Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17321495/),h,6,104522,DB00541,Vincristine
,26696583,elimination half-life,The median MTX elimination half-life was 21.7 h (range 9.4-204.4).,The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696583/),h,21.7,105605,DB00541,Vincristine
,3757156,T1/2 alpha,"The time-concentration curves of i.v.-treated patients (15 mg/m2 over 30 min) correspond to a three-compartment model with a T1/2 alpha of 12 min, a T1/2 beta of 93 min, and a slow elimination phase of 36 h.",Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757156/),min,12,110106,DB00541,Vincristine
,3757156,T1/2 beta,"The time-concentration curves of i.v.-treated patients (15 mg/m2 over 30 min) correspond to a three-compartment model with a T1/2 alpha of 12 min, a T1/2 beta of 93 min, and a slow elimination phase of 36 h.",Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757156/),min,93,110107,DB00541,Vincristine
,3757156,slow elimination phase,"The time-concentration curves of i.v.-treated patients (15 mg/m2 over 30 min) correspond to a three-compartment model with a T1/2 alpha of 12 min, a T1/2 beta of 93 min, and a slow elimination phase of 36 h.",Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757156/),h,36,110108,DB00541,Vincristine
,3757156,central compartment volume,"The central compartment volume was 26.22 and the distribution volume, 1381.9.",Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757156/),,26.22,110109,DB00541,Vincristine
,3757156,distribution volume,"The central compartment volume was 26.22 and the distribution volume, 1381.9.",Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757156/),,1381.9,110110,DB00541,Vincristine
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],299,110190,DB00541,Vincristine
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],384,110191,DB00541,Vincristine
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],245,110192,DB00541,Vincristine
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],321,110193,DB00541,Vincristine
,23802659,troughs,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),d,26-29,110194,DB00541,Vincristine
,23802659,t½,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),d,26-29,110195,DB00541,Vincristine
,25144346,bioavailability,The median bioavailability on i.p. administration was 76% for cyclophosphamide and 100% for vincristine.,Bioavailability of cyclophosphamide and vincristine after intraperitoneal administration in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25144346/),%,76,113888,DB00541,Vincristine
,25144346,bioavailability,The median bioavailability on i.p. administration was 76% for cyclophosphamide and 100% for vincristine.,Bioavailability of cyclophosphamide and vincristine after intraperitoneal administration in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25144346/),%,100,113889,DB00541,Vincristine
,25144346,areas under the curve,"Median areas under the curve for i.p. and intravenous administration were 11.4 and 16.0 ng h/ml for cyclophosphamide and 16.7 and 16.5 ng h/ml for vincristine, respectively.",Bioavailability of cyclophosphamide and vincristine after intraperitoneal administration in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25144346/),[h·ng] / [ml],11.4,113890,DB00541,Vincristine
,25144346,areas under the curve,"Median areas under the curve for i.p. and intravenous administration were 11.4 and 16.0 ng h/ml for cyclophosphamide and 16.7 and 16.5 ng h/ml for vincristine, respectively.",Bioavailability of cyclophosphamide and vincristine after intraperitoneal administration in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25144346/),[h·ng] / [ml],16.0,113891,DB00541,Vincristine
,25144346,areas under the curve,"Median areas under the curve for i.p. and intravenous administration were 11.4 and 16.0 ng h/ml for cyclophosphamide and 16.7 and 16.5 ng h/ml for vincristine, respectively.",Bioavailability of cyclophosphamide and vincristine after intraperitoneal administration in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25144346/),[h·ng] / [ml],16.7,113892,DB00541,Vincristine
,25144346,areas under the curve,"Median areas under the curve for i.p. and intravenous administration were 11.4 and 16.0 ng h/ml for cyclophosphamide and 16.7 and 16.5 ng h/ml for vincristine, respectively.",Bioavailability of cyclophosphamide and vincristine after intraperitoneal administration in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25144346/),[h·ng] / [ml],16.5,113893,DB00541,Vincristine
,31103789,half maximal inhibitory concentration,"The antitumor activity was characterized by 3-(4, 5-dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide assay, and half maximal inhibitory concentration values of VCR-liposomes spray-dried powder were 24.42 ± 1.88 nM and 55.28 ± 4.76 nM in MCF-7 and A549 cells, respectively.",Formulation and Characterization of Spray-Dried Powders Containing Vincristine-Liposomes for Pulmonary Delivery and Its Pharmacokinetic Evaluation From In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103789/),nM,24.42,115381,DB00541,Vincristine
,31103789,half maximal inhibitory concentration,"The antitumor activity was characterized by 3-(4, 5-dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide assay, and half maximal inhibitory concentration values of VCR-liposomes spray-dried powder were 24.42 ± 1.88 nM and 55.28 ± 4.76 nM in MCF-7 and A549 cells, respectively.",Formulation and Characterization of Spray-Dried Powders Containing Vincristine-Liposomes for Pulmonary Delivery and Its Pharmacokinetic Evaluation From In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103789/),nM,55.28,115382,DB00541,Vincristine
,24037082,oral bioavailability,Pharmacokinetic studies demonstrated relatively high oral bioavailability (71%) with distribution to both plasma and bone marrow.,The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24037082/),%,71,115865,DB00541,Vincristine
,12663724,area under concentration-time curve (AUC),"Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P =.06 and P =.07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micro mol/L x h, respectively) than in patients (n = 3) who did not (14 and 303 micro mol/L x h, respectively).",Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12663724/),[μmol] / [h·l],24,117533,DB00541,Vincristine
,12663724,area under concentration-time curve (AUC),"Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P =.06 and P =.07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micro mol/L x h, respectively) than in patients (n = 3) who did not (14 and 303 micro mol/L x h, respectively).",Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12663724/),[μmol] / [h·l],522,117534,DB00541,Vincristine
,12663724,area under concentration-time curve (AUC),"Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P =.06 and P =.07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micro mol/L x h, respectively) than in patients (n = 3) who did not (14 and 303 micro mol/L x h, respectively).",Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12663724/),[μmol] / [h·l],14,117535,DB00541,Vincristine
,12663724,cumulative AUC,"Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P =.06 and P =.07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micro mol/L x h, respectively) than in patients (n = 3) who did not (14 and 303 micro mol/L x h, respectively).",Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12663724/),[μmol] / [h·l],14,117536,DB00541,Vincristine
,12663724,cumulative AUC,"Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P =.06 and P =.07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micro mol/L x h, respectively) than in patients (n = 3) who did not (14 and 303 micro mol/L x h, respectively).",Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12663724/),[μmol] / [h·l],303,117537,DB00541,Vincristine
,6722774,half-life,Pharmacokinetic studies of diaziquone in the plasma of athymic mice indicated rapid clearance with a half-life of approximately 11.5 min.,Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6722774/),min,11.5,119287,DB00541,Vincristine
,27447545,CL),"Population estimates for parent drug (CL) and metabolite (CLm ) clearance were 62 l h-1 and 27 l h-1 , respectively.",Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27447545/),[l] / [h],62,121257,DB00541,Vincristine
,27447545,clearance,"Population estimates for parent drug (CL) and metabolite (CLm ) clearance were 62 l h-1 and 27 l h-1 , respectively.",Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27447545/),[l] / [h],27,121258,DB00541,Vincristine
,27447545,fraction metabolized to DOXol (Fm ),The fraction metabolized to DOXol (Fm ) was estimated at 0.22.,Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27447545/),,0.22,121259,DB00541,Vincristine
,12839283,distribution half-life,"The median value (and range) for distribution half-life was 6.4 min (0.8-11.8), elimination half-life 1014 min (258-2570), volume of distribution 445 L/m2 (137-1241) and total body clearance 362 ml/min/m2 (134-2553).",Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839283/),min,6.4,122866,DB00541,Vincristine
,12839283,elimination half-life,"The median value (and range) for distribution half-life was 6.4 min (0.8-11.8), elimination half-life 1014 min (258-2570), volume of distribution 445 L/m2 (137-1241) and total body clearance 362 ml/min/m2 (134-2553).",Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839283/),min,1014,122867,DB00541,Vincristine
,12839283,volume of distribution,"The median value (and range) for distribution half-life was 6.4 min (0.8-11.8), elimination half-life 1014 min (258-2570), volume of distribution 445 L/m2 (137-1241) and total body clearance 362 ml/min/m2 (134-2553).",Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839283/),[l] / [m2],445,122868,DB00541,Vincristine
,12839283,total body clearance,"The median value (and range) for distribution half-life was 6.4 min (0.8-11.8), elimination half-life 1014 min (258-2570), volume of distribution 445 L/m2 (137-1241) and total body clearance 362 ml/min/m2 (134-2553).",Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839283/),[ml] / [m2·min],362,122869,DB00541,Vincristine
,10811501,maximum tolerated dose,Using this protracted i.v. infusion schedule the maximum tolerated dose is 1.2 mg/m2/72 hours.,A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10811501/),[mg] / [72·h·m2],1.2,123233,DB00541,Vincristine
,15726371,area under the plasma concentration-time curve (AUC),"Non-compartmental analysis yielded an area under the plasma concentration-time curve (AUC) for Dx of 566 mug h L(-1), a maximum plasma concentration (c(max)) of 599 mug L(-1) and an elimination half-life (t(1/2)) of 30.8 h.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),[h·μg] / [l],566,125229,DB00541,Vincristine
,15726371,maximum plasma concentration (c(max)),"Non-compartmental analysis yielded an area under the plasma concentration-time curve (AUC) for Dx of 566 mug h L(-1), a maximum plasma concentration (c(max)) of 599 mug L(-1) and an elimination half-life (t(1/2)) of 30.8 h.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),[μg] / [l],599,125230,DB00541,Vincristine
,15726371,elimination half-life (t(1/2)),"Non-compartmental analysis yielded an area under the plasma concentration-time curve (AUC) for Dx of 566 mug h L(-1), a maximum plasma concentration (c(max)) of 599 mug L(-1) and an elimination half-life (t(1/2)) of 30.8 h.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),h,30.8,125231,DB00541,Vincristine
,15726371,clearance,"Model estimate for Dx clearance was 61.8 L h(-1), for intercompartmental clearance (Q) 112 L h(-1), for the volume of the central compartment (V(1)) 23.3 L, and for the volume of the peripheral compartment (V(2)) 1,130 L.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),[l] / [h],61.8,125232,DB00541,Vincristine
,15726371,intercompartmental clearance (Q),"Model estimate for Dx clearance was 61.8 L h(-1), for intercompartmental clearance (Q) 112 L h(-1), for the volume of the central compartment (V(1)) 23.3 L, and for the volume of the peripheral compartment (V(2)) 1,130 L.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),[l] / [h],112,125233,DB00541,Vincristine
,15726371,volume of the central compartment (V(1)),"Model estimate for Dx clearance was 61.8 L h(-1), for intercompartmental clearance (Q) 112 L h(-1), for the volume of the central compartment (V(1)) 23.3 L, and for the volume of the peripheral compartment (V(2)) 1,130 L.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),l,23.3,125234,DB00541,Vincristine
,15726371,volume of the peripheral compartment (V(2)),"Model estimate for Dx clearance was 61.8 L h(-1), for intercompartmental clearance (Q) 112 L h(-1), for the volume of the central compartment (V(1)) 23.3 L, and for the volume of the peripheral compartment (V(2)) 1,130 L.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),l,"1,130",125235,DB00541,Vincristine
,8246021,dose-normalized area under the plasma carboplatin concentration versus time curve (AUC),The dose-normalized area under the plasma carboplatin concentration versus time curve (AUC) ranged from 3.1 to 9.6 mg/mL.min/400 mg/m2 and there was only a weak linear relationship between carboplatin dose and AUC (R2 = .31).,Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8246021/),[mg] / [400·m2·mg·min·ml],3.1 to 9.6,125790,DB00541,Vincristine
,32800518,overall un,"The overall unconfirmed response rate was 84%, and the confirmed complete response rate was 44%.",Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800518/),%,84,126296,DB00541,Vincristine
,32800518,confirmed complete response rate,"The overall unconfirmed response rate was 84%, and the confirmed complete response rate was 44%.",Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800518/),%,44,126297,DB00541,Vincristine
,32800518,progression free-survival,The median progression free-survival was 27.6 months.,Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800518/),month,27.6,126298,DB00541,Vincristine
,32800518,total body residence time,The median total body residence time was 94.5 hours.,Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800518/),h,94.5,126299,DB00541,Vincristine
,3855472,half-life (t 1/2),[3H]VBL exhibited two phases of elimination: a rapid early phase [half-life (t 1/2) of approximately equal to 30 min] and a prolonged terminal phase (t 1/2 of approximately equal to 17 hr).,Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855472/),min,30,126941,DB00541,Vincristine
,3855472,terminal phase (t 1/2,[3H]VBL exhibited two phases of elimination: a rapid early phase [half-life (t 1/2) of approximately equal to 30 min] and a prolonged terminal phase (t 1/2 of approximately equal to 17 hr).,Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855472/),h,17,126942,DB00541,Vincristine
,1545439,LD10,"The LD10 was 11.7 +/- 0.7 mg/m2 (mean +/- SD), and the LD50 was 14.7 +/- 0.6 mg/m2.",Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545439/),[mg] / [m2],11.7,127821,DB00541,Vincristine
,1545439,LD50,"The LD10 was 11.7 +/- 0.7 mg/m2 (mean +/- SD), and the LD50 was 14.7 +/- 0.6 mg/m2.",Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545439/),[mg] / [m2],14.7,127822,DB00541,Vincristine
,1545439,half-life [t 1/2] alpha,"Rhizoxin pharmacokinetics were best described by a two-compartment open model (half-life [t 1/2] alpha = 4.4 minutes +/- 0.9 minute [mean +/- SD], and t 1/2 beta = 84 minutes +/- 20 minutes at 12 mg/m2) and found to be nonlinear with respect to dose.",Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545439/),min,4.4,127823,DB00541,Vincristine
,1545439,t 1/2 beta,"Rhizoxin pharmacokinetics were best described by a two-compartment open model (half-life [t 1/2] alpha = 4.4 minutes +/- 0.9 minute [mean +/- SD], and t 1/2 beta = 84 minutes +/- 20 minutes at 12 mg/m2) and found to be nonlinear with respect to dose.",Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545439/),min,84,127824,DB00541,Vincristine
,1545439,AUC,"At doses of 1.2, 6, and 12 mg/m2, the respective AUC values were 1.3, 22.4, and 70.6 microM x minute.",Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545439/),min·μM,1.3,127825,DB00541,Vincristine
,1545439,AUC,"At doses of 1.2, 6, and 12 mg/m2, the respective AUC values were 1.3, 22.4, and 70.6 microM x minute.",Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545439/),min·μM,22.4,127826,DB00541,Vincristine
,1545439,AUC,"At doses of 1.2, 6, and 12 mg/m2, the respective AUC values were 1.3, 22.4, and 70.6 microM x minute.",Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545439/),min·μM,70.6,127827,DB00541,Vincristine
,1545439,AUC,"From these data, a target AUC value of 28 microM x minute (40% of the LD10 AUC) was derived.",Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545439/),min·μM,28,127828,DB00541,Vincristine
,1545439,AUC,"The AUC values at the human MTD (2.6 mg/m2) were in the range of 0.41-1.01 microM x minute, considerably lower than the target AUC of 28 microM x minute.",Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545439/),min·μM,0.41-1.01,127829,DB00541,Vincristine
,1545439,AUC,"The AUC values at the human MTD (2.6 mg/m2) were in the range of 0.41-1.01 microM x minute, considerably lower than the target AUC of 28 microM x minute.",Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545439/),min·μM,28,127830,DB00541,Vincristine
,6359081,terminal half-life,Pharmacokinetic studies indicate that vindesine exhibits a triphasic elimination pattern with a terminal half-life of 24.2 hours.,"Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new vinca alkaloid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6359081/),h,24.2,128127,DB00541,Vincristine
,33095287,maximum tolerated dose (MTD),"In Part D, the maximum tolerated dose (MTD) was exceeded at 165 mg/m2/dose of crizotinib cMS.","Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33095287/),mg,165,138074,DB00541,Vincristine
,12006542,time required to reach the maximum plasma drug concentration (t(max)),"Our findings indicate that LFM-A13 is quickly absorbed, with the time required to reach the maximum plasma drug concentration (t(max)) being 10-18 min after i.p. administration with nearly complete bioavailability.","In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006542/),min,10-18,143386,DB00541,Vincristine
,12006542,elimination half-life,LFM-A13 had an elimination half-life of 17-32 min after i.p. administration at dose levels of 10-50 mg/kg.,"In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006542/),min,17-32,143387,DB00541,Vincristine
,12006542,survival time,LFM-A13 prolonged the median survival time of VPL-treated mice from 37 to 58 days.,"In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006542/),d,37 to 58,143388,DB00541,Vincristine
,21372831,overall response rate (ORR),"The overall response rate (ORR) was 45.5%, and the CR rate was 27.3%.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),%,45.5,147623,DB00541,Vincristine
,21372831,CR rate,"The overall response rate (ORR) was 45.5%, and the CR rate was 27.3%.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),%,27,147624,DB00541,Vincristine
,21372831,progression-free survival (PFS) rate,"The 1-year overall survival rate was 45.5%, and the median progression-free survival (PFS) rate was 6.5 [95% confidence interval (95% CI) 3.17-19.02] with a survival rate of 11.5 months (95% CI 6.65-16.36).",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),,6.5,147625,DB00541,Vincristine
,21372831,survival rate,"The 1-year overall survival rate was 45.5%, and the median progression-free survival (PFS) rate was 6.5 [95% confidence interval (95% CI) 3.17-19.02] with a survival rate of 11.5 months (95% CI 6.65-16.36).",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),,11,147626,DB00541,Vincristine
,21372831,plasma concentration,The PLD plasma concentration from nine patients ranged from 1.7036 to 9.2207 mg·L(-1) after administration of the CCOP regimen (0-168 h).,Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[mg] / [l],1.7036 to 9.2207,147627,DB00541,Vincristine
,21372831,AUC(0-∞),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[mg] / [h·l],910.76,147628,DB00541,Vincristine
,21372831,CL,"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[l] / [(m)^2·h],0.043,147629,DB00541,Vincristine
,21372831,CL,"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),h,68.40,147630,DB00541,Vincristine
,21372831,t(1/2),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[l] / [(m)^2·h],0.043,147631,DB00541,Vincristine
,21372831,t(1/2),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),h,68.40,147632,DB00541,Vincristine
,21372831,V(d),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[l] / [m(2],3.56,147633,DB00541,Vincristine
more,34219092,serum half-life,"The pharmacokinetics of rituximab differs substantially among individuals and its serum half-life is approximately more than 500 hours; therefore, the peak concentration increases cumulatively by weekly infusion.",[Optimization of rituximab dosing schedule in R-CHOP therapy for diffuse large B-cell lymphoma]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34219092/),h,500,148482,DB00541,Vincristine
,2549204,overall response rate,"In the 24-hour arm, two patients achieved a partial remission, resulting in an overall response rate of 10%.",A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2549204/),%,10,151311,DB00541,Vincristine
,2549204,overall response rate,"In the 5-day schedule, 16 patients had a partial response and one had a complete remission, producing an overall response rate of 89%, which was significantly superior to that in the 24-hour arm (P less than .001).",A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2549204/),%,89,151312,DB00541,Vincristine
,2549204,duration of remission,The median duration of remission to etoposide in the 5-day arm was 4.5 months.,A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2549204/),month,4.5,151313,DB00541,Vincristine
excess,2549204,response rate,The response rate to single-agent etoposide using an efficacious schedule in extensive small-cell lung cancer has been determined to be in excess of 80%.,A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2549204/),%,80,151314,DB00541,Vincristine
,3152911,First-phase elimination half-lives (t1/2(alpha)),First-phase elimination half-lives (t1/2(alpha)) of MTX and 7-hydroxy-methotrexate (7-OH-MTX) after 21 infusions were 2.7 +/- 0.4 h and 6.5 +/- 1.8 h (mean +/- SD).,High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,2.7,155899,DB00541,Vincristine
,3152911,First-phase elimination half-lives (t1/2(alpha)),First-phase elimination half-lives (t1/2(alpha)) of MTX and 7-hydroxy-methotrexate (7-OH-MTX) after 21 infusions were 2.7 +/- 0.4 h and 6.5 +/- 1.8 h (mean +/- SD).,High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,6.5,155900,DB00541,Vincristine
,3152911,first-phase elimination half-lives (t1/2(alpha],"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,4.2,155901,DB00541,Vincristine
,3152911,first-phase elimination half-lives (t1/2(alpha],"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,9.9,155902,DB00541,Vincristine
,3152911,second-phase elimination half-lives (t1/2(beta)),"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,43,155903,DB00541,Vincristine
,3152911,second-phase elimination half-lives (t1/2(beta)),"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,58,155904,DB00541,Vincristine
,26291333,EC50,"FD18 is a potent (EC50 = 148 nM for paclitaxel), safe (selective index = 574), and selective P-glycoprotein (P-gp) modulator.","A New Class of Safe, Potent, and Specific P-gp Modulator: Flavonoid Dimer FD18 Reverses P-gp-Mediated Multidrug Resistance in Human Breast Xenograft in Vivo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26291333/),nM,148,155958,DB00541,Vincristine
,26291333,EC50,Pharmacokinetics studies indicated that intraperitoneal administration of 45 mg/kg FD18 was enough to maintain a plasma level above EC50 (148 nM) for more than 600 min.,"A New Class of Safe, Potent, and Specific P-gp Modulator: Flavonoid Dimer FD18 Reverses P-gp-Mediated Multidrug Resistance in Human Breast Xenograft in Vivo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26291333/),nM,148,155959,DB00541,Vincristine
,34111732,flow rate,"A gradient elution of mobile phase A (methanol-0.2 % formic acid in water, 20:80 v/v) and mobile phase B (methanol-0.2 % formic acid in water, 80:20 v/v) was used with a flow rate of 0.4 mL/min and a total run time of 5 min.",Simultaneous quantification of vincristine and its major M1 metabolite from dried blood spot samples of Kenyan pediatric cancer patients by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34111732/),[ml] / [min],0.4,159313,DB00541,Vincristine
,34111732,total run time,"A gradient elution of mobile phase A (methanol-0.2 % formic acid in water, 20:80 v/v) and mobile phase B (methanol-0.2 % formic acid in water, 80:20 v/v) was used with a flow rate of 0.4 mL/min and a total run time of 5 min.",Simultaneous quantification of vincristine and its major M1 metabolite from dried blood spot samples of Kenyan pediatric cancer patients by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34111732/),min,5,159314,DB00541,Vincristine
,34111732,extraction recovery,"The extraction recovery of VCR from DBS paper was 35.3-39.4 % and 10.4-13.4 % for M1, with no carryover observed for both analytes.",Simultaneous quantification of vincristine and its major M1 metabolite from dried blood spot samples of Kenyan pediatric cancer patients by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34111732/),%,35.3-39.4,159315,DB00541,Vincristine
,34111732,extraction recovery,"The extraction recovery of VCR from DBS paper was 35.3-39.4 % and 10.4-13.4 % for M1, with no carryover observed for both analytes.",Simultaneous quantification of vincristine and its major M1 metabolite from dried blood spot samples of Kenyan pediatric cancer patients by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34111732/),%,10.4-13.4,159316,DB00541,Vincristine
,30689002,CL,"The population PK parameters for CP were: CL = 3.58 L/h, Vmale = 32.2 L, and Vfemale = 28.7 L.",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),[l] / [h],3.58,161752,DB00541,Vincristine
,30689002,Vmale,"The population PK parameters for CP were: CL = 3.58 L/h, Vmale = 32.2 L, and Vfemale = 28.7 L.",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,32.2,161753,DB00541,Vincristine
,30689002,Vfemale,"The population PK parameters for CP were: CL = 3.58 L/h, Vmale = 32.2 L, and Vfemale = 28.7 L.",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,28.7,161754,DB00541,Vincristine
,30689002,CL,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),[l] / [h],51.1,161755,DB00541,Vincristine
,30689002,Q,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),[l] / [h],49.6,161756,DB00541,Vincristine
,30689002,V1,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,29.4,161757,DB00541,Vincristine
,30689002,V2,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,"1,130",161758,DB00541,Vincristine
,30689002,V1,VCR increases DOXO V1 from 29.4 L to 57.5 L (p = 0.02).,Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,29.4,161759,DB00541,Vincristine
,30689002,V1,VCR increases DOXO V1 from 29.4 L to 57.5 L (p = 0.02).,Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,57.5,161760,DB00541,Vincristine
,3476358,area under the curve (AUC) 0-24 h,A large variability was observed with respect to (1) the plasma area under the curve (AUC) 0-24 h (range: 0.06-0.37 nmol X h/ml); (2) the white cell AUC 0-24 h (range: 0-441 nmol X h/10(9) cells); and (3) the 1 h bone marrow concentration (range: 0-27 nmol/10(9) cells).,Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3476358/),[h·nM] / [ml],0.06-0.37,162790,DB00541,Vincristine
,3476358,AUC 0-24 h,A large variability was observed with respect to (1) the plasma area under the curve (AUC) 0-24 h (range: 0.06-0.37 nmol X h/ml); (2) the white cell AUC 0-24 h (range: 0-441 nmol X h/10(9) cells); and (3) the 1 h bone marrow concentration (range: 0-27 nmol/10(9) cells).,Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3476358/),[h·nM] / [10(9)·cells],0-441,162791,DB00541,Vincristine
,32222808,volume of distribution,"Geometric mean volume of distribution and clearance of acMMAE ranged from 57.3 to 95.6 mL/kg and 12.7 to 18.2 mL/kg/day, respectively.",Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222808/),[ml] / [kg],57.3 to 95.6,163246,DB00541,Vincristine
,32222808,clearance,"Geometric mean volume of distribution and clearance of acMMAE ranged from 57.3 to 95.6 mL/kg and 12.7 to 18.2 mL/kg/day, respectively.",Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222808/),[ml] / [d·kg],12.7 to 18.2,163247,DB00541,Vincristine
,32222808,elimination half-life,acMMAE exhibited multi-exponential decay (elimination half-life ~ 1 week).,Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222808/),week,1,163248,DB00541,Vincristine
,33684722,flow rate,Separation of vincristine and the internal standard [2H3]-vincristine was achieved on an Accucore aQ column with a gradient mobile phase delivered at a flow rate of 0.4 mL/min and a run time of 2.2 min.,Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33684722/),[ml] / [min],0.4,164756,DB00541,Vincristine
,33684722,run time,Separation of vincristine and the internal standard [2H3]-vincristine was achieved on an Accucore aQ column with a gradient mobile phase delivered at a flow rate of 0.4 mL/min and a run time of 2.2 min.,Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33684722/),min,2.2,164757,DB00541,Vincristine
,33684722,matrix effect,"The matrix effect and extraction recovery for vincristine were ranging 108-110% and 88.4-107%, respectively.",Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33684722/),%,108-110,164758,DB00541,Vincristine
,33684722,extraction recovery,"The matrix effect and extraction recovery for vincristine were ranging 108-110% and 88.4-107%, respectively.",Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33684722/),%,88.4-107,164759,DB00541,Vincristine
,8820952,peak concentrations,"Pharmacokinetic analysis revealed median peak concentrations of dexverapamil and its metabolite, nor-dexverapamil, of 1.66 mumol/l and 1.58 mumol/l, respectively.",Clinical reversal of multidrug resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],1.66,165049,DB00541,Vincristine
,8820952,peak concentrations,"Pharmacokinetic analysis revealed median peak concentrations of dexverapamil and its metabolite, nor-dexverapamil, of 1.66 mumol/l and 1.58 mumol/l, respectively.",Clinical reversal of multidrug resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],1.58,165050,DB00541,Vincristine
,8820952,peak total reversing concentration,"Since both are comparable antagonists, a median peak total reversing concentration of 3.24 mumol/l was achieved.",Clinical reversal of multidrug resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],3.24,165051,DB00541,Vincristine
,7307229,half-lives,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,2.6,171231,DB00541,Vincristine
,7307229,half-lives,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,41,171232,DB00541,Vincristine
,7307229,half-lives,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,"1,531",171233,DB00541,Vincristine
,7307229,half-lives,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),h,25.5,171234,DB00541,Vincristine
,7307229,alpha,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,2.6,171235,DB00541,Vincristine
,7307229,beta,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,2.6,171236,DB00541,Vincristine
,7307229,beta,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,41,171237,DB00541,Vincristine
,7307229,beta,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,"1,531",171238,DB00541,Vincristine
,7307229,gamma,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,2.6,171239,DB00541,Vincristine
,7307229,gamma,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,41,171240,DB00541,Vincristine
,7307229,gamma,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,"1,531",171241,DB00541,Vincristine
,7307229,gamma,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),h,25.5,171242,DB00541,Vincristine
,7307229,apparent volume of the central compartment,"The mean apparent volume of the central compartment was 3.25 l, and the the volume of distribution per 1.73 m2 body surface area at steady state was 215.9 l.",Pharmacokinetics of vincristine sulfate in children. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),l,3.25,171243,DB00541,Vincristine
,7307229,volume of distribution per,"The mean apparent volume of the central compartment was 3.25 l, and the the volume of distribution per 1.73 m2 body surface area at steady state was 215.9 l.",Pharmacokinetics of vincristine sulfate in children. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),l,215.9,171244,DB00541,Vincristine
,7307229,body surface area at steady state,"The mean apparent volume of the central compartment was 3.25 l, and the the volume of distribution per 1.73 m2 body surface area at steady state was 215.9 l.",Pharmacokinetics of vincristine sulfate in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),l,215.9,171245,DB00541,Vincristine
,7307229,k12,"In a three-compartment open model, the first-order distribution and elimination rate constants (min-1) of vincristine were as follows: k12, 0.088; k13, 0.121; k21, 0.028; k31, 0.0026; k10, 0.045.",Pharmacokinetics of vincristine sulfate in children. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),1/[min],0.088,171246,DB00541,Vincristine
,7307229,k13,"In a three-compartment open model, the first-order distribution and elimination rate constants (min-1) of vincristine were as follows: k12, 0.088; k13, 0.121; k21, 0.028; k31, 0.0026; k10, 0.045.",Pharmacokinetics of vincristine sulfate in children. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),,0.121,171247,DB00541,Vincristine
,7307229,k21,"In a three-compartment open model, the first-order distribution and elimination rate constants (min-1) of vincristine were as follows: k12, 0.088; k13, 0.121; k21, 0.028; k31, 0.0026; k10, 0.045.",Pharmacokinetics of vincristine sulfate in children. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),,0.028,171248,DB00541,Vincristine
,7307229,k31,"In a three-compartment open model, the first-order distribution and elimination rate constants (min-1) of vincristine were as follows: k12, 0.088; k13, 0.121; k21, 0.028; k31, 0.0026; k10, 0.045.",Pharmacokinetics of vincristine sulfate in children. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),,0.0026,171249,DB00541,Vincristine
,7307229,k10,"In a three-compartment open model, the first-order distribution and elimination rate constants (min-1) of vincristine were as follows: k12, 0.088; k13, 0.121; k21, 0.028; k31, 0.0026; k10, 0.045.",Pharmacokinetics of vincristine sulfate in children. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),,0.045,171250,DB00541,Vincristine
,7307229,plasma clearance,"The plasma clearance was 146.2 ml/min per 1.73 m2, while the AUC0 infinity was 27,816 nM . min.",Pharmacokinetics of vincristine sulfate in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),[ml] / [1.73·m2·min],146.2,171251,DB00541,Vincristine
,7307229,AUC0 infinity,"The plasma clearance was 146.2 ml/min per 1.73 m2, while the AUC0 infinity was 27,816 nM . min.",Pharmacokinetics of vincristine sulfate in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min·nM,"27,816",171252,DB00541,Vincristine
,7307229,biological half-life,"The low elimination rate constant from poorly perfused tissues to blood plasma (k31), a large apparent volume of distribution, and a long biological half-life (25.5 h) indicate avid tissue binding from which a slow release of the drug from the body tissues occurs.",Pharmacokinetics of vincristine sulfate in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),h,25.5,171253,DB00541,Vincristine
,17273824,plasma peak concentration,The plasma peak concentration of Tet was about 2 micromol/L and not less than 1 micromol/L until 18 h following Tet administration (i.p.) at 30 mg/kg.,Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17273824/),[μM] / [l],2,173364,DB00541,Vincristine
less,17273824,plasma peak concentration,The plasma peak concentration of Tet was about 2 micromol/L and not less than 1 micromol/L until 18 h following Tet administration (i.p.) at 30 mg/kg.,Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17273824/),[μM] / [l],1,173365,DB00541,Vincristine
,21665557,flow rate,"Chromatographic separation of VCR and IS was achieved by a Dikma Dimonsil C₁₈ column (200 mm×4.6 mm) with the mobile phase consisting of 0.02 M sodium dihydrogen phosphate-methanol (36:64, v/v, pH=4.7) at a flow rate of 1.0 mL/min.",An HPLC method for the pharmacokinetic study of vincristine sulfate-loaded PLGA-PEG nanoparticle formulations after injection to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665557/),[ml] / [min],1.0,173582,DB00541,Vincristine
over,21665557,method,The average method recoveries for vincristine from spiked plasma at all QC levels were over 83%; and extraction recoveries were between 66 and 70%.,An HPLC method for the pharmacokinetic study of vincristine sulfate-loaded PLGA-PEG nanoparticle formulations after injection to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665557/),%,83,173583,DB00541,Vincristine
over,21665557,recoveries,The average method recoveries for vincristine from spiked plasma at all QC levels were over 83%; and extraction recoveries were between 66 and 70%.,An HPLC method for the pharmacokinetic study of vincristine sulfate-loaded PLGA-PEG nanoparticle formulations after injection to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665557/),%,83,173584,DB00541,Vincristine
,21665557,extraction recoveries,The average method recoveries for vincristine from spiked plasma at all QC levels were over 83%; and extraction recoveries were between 66 and 70%.,An HPLC method for the pharmacokinetic study of vincristine sulfate-loaded PLGA-PEG nanoparticle formulations after injection to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665557/),%,66 and 70,173585,DB00541,Vincristine
,8547077,maximum rhIL-3 serum concentration,Following s.c. injection on cycle day 2. the maximum rhIL-3 serum concentration ranged from 289 pg/ml (0.5 micrograms/kg) to 4690 pg/ml (10 micrograms/kg).,Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),[pg] / [ml],289,175451,DB00541,Vincristine
,8547077,maximum rhIL-3 serum concentration,Following s.c. injection on cycle day 2. the maximum rhIL-3 serum concentration ranged from 289 pg/ml (0.5 micrograms/kg) to 4690 pg/ml (10 micrograms/kg).,Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),[pg] / [ml],4690,175452,DB00541,Vincristine
,8547077,elimination half-life T1/2 beta,"The elimination half-life T1/2 beta was 160 min for 0.5 micrograms/kg and 134 min for 10 micrograms/kg, with no apparent dose relationship.",Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),min,160,175453,DB00541,Vincristine
,8547077,elimination half-life T1/2 beta,"The elimination half-life T1/2 beta was 160 min for 0.5 micrograms/kg and 134 min for 10 micrograms/kg, with no apparent dose relationship.",Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),min,134,175454,DB00541,Vincristine
,8547077,systemic clearance,The systemic clearance of 3.0-6.0 ml/min/kg was comparable at all dose levels.,Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),[ml] / [kg·min],3.0-6.0,175455,DB00541,Vincristine
,16809798,area under the plasma concentration-time curve from time zero to infinity,The area under the plasma concentration-time curve from time zero to infinity of total vincristine in plasma ranged from 4933 to 40495 h.ng/mL and total clearance ranged from 131 to 445 mL/h.,Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16809798/),[h·ng] / [ml],4933 to 40495,175531,DB00541,Vincristine
,16809798,total clearance,The area under the plasma concentration-time curve from time zero to infinity of total vincristine in plasma ranged from 4933 to 40495 h.ng/mL and total clearance ranged from 131 to 445 mL/h.,Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16809798/),[ml] / [h],131 to 445,175532,DB00541,Vincristine
,16809798,volume of distribution at steady state,"The volume of distribution at steady state was 2650 +/- 731 mL, indicating VSLI was mainly confined within the plasma.",Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16809798/),ml,2650,175533,DB00541,Vincristine
below,16809798,trough plasma levels,"The pharmacokinetic parameters were similar between cycles 1 and 3, and trough plasma levels of total vincristine were below the level of quantitation of 1 ng/mL.",Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16809798/),[ng] / [ml],1,175534,DB00541,Vincristine
,23907766,CL,"In contrast to the rapid CL and wide tissue distribution of non-liposomal VCR, VSLI circulates in plasma for a prolonged period of time, with a slow CL of 345 mL/h and relatively small Vd of 3,570 mL.",Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23907766/),[ml] / [h],345,177101,DB00541,Vincristine
,23907766,Vd,"In contrast to the rapid CL and wide tissue distribution of non-liposomal VCR, VSLI circulates in plasma for a prolonged period of time, with a slow CL of 345 mL/h and relatively small Vd of 3,570 mL.",Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23907766/),ml,"3,570",177102,DB00541,Vincristine
,7622296,distribution phase plasma half-life,Encapsulation of vincristine in sterically stabilized liposomes (SL-VCR) prolonged the drug's distribution phase plasma half-life in rats from 0.22 to 10.5 hr.,Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7622296/),h,0,178263,DB00541,Vincristine
,7622296,distribution phase plasma half-life,Encapsulation of vincristine in sterically stabilized liposomes (SL-VCR) prolonged the drug's distribution phase plasma half-life in rats from 0.22 to 10.5 hr.,Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7622296/),h,10,178264,DB00541,Vincristine
,18229621,entrapment ratio,The average particle size of VCR-T prepared was 63 nm with an entrapment ratio of 59%.,[Transdermal and lymph targeting transfersomes of vincristine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18229621/),,59,178422,DB00541,Vincristine
,18229621,accumulation permeation percentage,"The in vitro transdermal research with modified Franz cell showed that VCR-T permeated through the skin in accordance with polynomial equation, and with an accumulation permeation percentage of 67.4% up to 12 h.",[Transdermal and lymph targeting transfersomes of vincristine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18229621/),%,67.4,178423,DB00541,Vincristine
,34023919,area under the concentration-time curve (AUC),"The median (coefficient of variation, CV%) area under the concentration-time curve (AUC) was 332 ng/mL·h. (110%); clearance was 4.6 L/h/m2 (90%); half-life was 25 h (60%).",Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34023919/),[ng] / [h·ml],332,178967,DB00541,Vincristine
,34023919,clearance,"The median (coefficient of variation, CV%) area under the concentration-time curve (AUC) was 332 ng/mL·h. (110%); clearance was 4.6 L/h/m2 (90%); half-life was 25 h (60%).",Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34023919/),[l] / [h·m2],4.6,178968,DB00541,Vincristine
,34023919,half-life,"The median (coefficient of variation, CV%) area under the concentration-time curve (AUC) was 332 ng/mL·h. (110%); clearance was 4.6 L/h/m2 (90%); half-life was 25 h (60%).",Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34023919/),h,25,178969,DB00541,Vincristine
,34023919,AUC,The median (CV%) AUC was 78 ng/mL·h (98%); clearance was 17.2 L/h/m2 (67%); half-life was 14.6 h (73%).,Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34023919/),[ng] / [h·ml],78,178970,DB00541,Vincristine
,34023919,clearance,The median (CV%) AUC was 78 ng/mL·h (98%); clearance was 17.2 L/h/m2 (67%); half-life was 14.6 h (73%).,Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34023919/),[l] / [h·m2],17.2,178971,DB00541,Vincristine
,34023919,half-life,The median (CV%) AUC was 78 ng/mL·h (98%); clearance was 17.2 L/h/m2 (67%); half-life was 14.6 h (73%).,Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34023919/),h,14.6,178972,DB00541,Vincristine
,26661090,half-life (T1/2),"In contrast to standard vincristine, which had a multi-exponential plasma disappearance curve with a median initial (EOI to 30 min post-infusion) half-life (T1/2) of 4.8 min (range, 4.4-5.0 min) and terminal T1/2 of 24.3 h, a near-monoexponential curve with a median T1/2 of 17.9 h (range, 13.9-21.5 h) hours was calculated with VSLI.","Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661090/),min,4.8,179351,DB00541,Vincristine
,26661090,terminal T1/2,"In contrast to standard vincristine, which had a multi-exponential plasma disappearance curve with a median initial (EOI to 30 min post-infusion) half-life (T1/2) of 4.8 min (range, 4.4-5.0 min) and terminal T1/2 of 24.3 h, a near-monoexponential curve with a median T1/2 of 17.9 h (range, 13.9-21.5 h) hours was calculated with VSLI.","Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661090/),h,24.3,179352,DB00541,Vincristine
,26661090,T1/2,"In contrast to standard vincristine, which had a multi-exponential plasma disappearance curve with a median initial (EOI to 30 min post-infusion) half-life (T1/2) of 4.8 min (range, 4.4-5.0 min) and terminal T1/2 of 24.3 h, a near-monoexponential curve with a median T1/2 of 17.9 h (range, 13.9-21.5 h) hours was calculated with VSLI.","Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661090/),h,17.9,179353,DB00541,Vincristine
,26661090,ratios Cl VCR:Cl VSLI,"The ratios Cl VCR:Cl VSLI for the individual NHP were 300, 463 and 477.","Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates. ",Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661090/),,300,179354,DB00541,Vincristine
,26661090,ratios Cl VCR:Cl VSLI,"The ratios Cl VCR:Cl VSLI for the individual NHP were 300, 463 and 477.","Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates. ",Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661090/),,463,179355,DB00541,Vincristine
,26661090,ratios Cl VCR:Cl VSLI,"The ratios Cl VCR:Cl VSLI for the individual NHP were 300, 463 and 477.","Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates. ",Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661090/),,477,179356,DB00541,Vincristine
,20962707,Residual concentration,Residual concentration of AMD was 0.18 ± 0.02 ng/mL or 0.16% of the initial infusion concentration.,Approaches to clear residual chemotherapeutics from indwelling catheters in children with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20962707/),[ng] / [ml],0.18,179823,DB00541,Vincristine
,20962707,Residual concentration,Residual concentration of AMD was 0.18 ± 0.02 ng/mL or 0.16% of the initial infusion concentration.,Approaches to clear residual chemotherapeutics from indwelling catheters in children with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20962707/),%,0.16,179824,DB00541,Vincristine
,6690071,terminal half-lives,"The average terminal half-lives of vincristine, vinblastine, and vindesine in the serum were 189, 152, and 175 min, respectively.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),min,189,181217,DB00541,Vincristine
,6690071,terminal half-lives,"The average terminal half-lives of vincristine, vinblastine, and vindesine in the serum were 189, 152, and 175 min, respectively.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),min,152,181218,DB00541,Vincristine
,6690071,terminal half-lives,"The average terminal half-lives of vincristine, vinblastine, and vindesine in the serum were 189, 152, and 175 min, respectively.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),min,175,181219,DB00541,Vincristine
,6690071,areas under the alkaloid concentration-time curve from 0 to infinity,"The areas under the alkaloid concentration-time curve from 0 to infinity for these drugs for a 1-mg dose were as follows: vincristine, 26,572 nM x min; vinblastine, 16,745 nM x min; and vindesine, 12,708 nM x min.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),min·nM,"26,572",181220,DB00541,Vincristine
,6690071,areas under the alkaloid concentration-time curve from 0 to infinity,"The areas under the alkaloid concentration-time curve from 0 to infinity for these drugs for a 1-mg dose were as follows: vincristine, 26,572 nM x min; vinblastine, 16,745 nM x min; and vindesine, 12,708 nM x min.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),min·nM,"16,745",181221,DB00541,Vincristine
,6690071,areas under the alkaloid concentration-time curve from 0 to infinity,"The areas under the alkaloid concentration-time curve from 0 to infinity for these drugs for a 1-mg dose were as follows: vincristine, 26,572 nM x min; vinblastine, 16,745 nM x min; and vindesine, 12,708 nM x min.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),min·nM,"12,708",181222,DB00541,Vincristine
,6690071,clearance rate,The clearance rate (ml/min/kg) for vincristine (4.8) was slightly lower than that for vinblastine (7.0) or vindesine (7.8).,"Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),[ml] / [kg·min],4.8,181223,DB00541,Vincristine
,6690071,clearance rate,The clearance rate (ml/min/kg) for vincristine (4.8) was slightly lower than that for vinblastine (7.0) or vindesine (7.8).,"Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),[ml] / [kg·min],7.0,181224,DB00541,Vincristine
,6690071,clearance rate,The clearance rate (ml/min/kg) for vincristine (4.8) was slightly lower than that for vinblastine (7.0) or vindesine (7.8).,"Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),[ml] / [kg·min],7.8,181225,DB00541,Vincristine
,6690071,apparent volumes of distribution,"The apparent volumes of distribution for vincristine, vinblastine, and vindesine were, respectively, 1.3, 1.5, and 1.9 l/kg body weight.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),[l] / [body·kg·weight],1.3,181226,DB00541,Vincristine
,6690071,apparent volumes of distribution,"The apparent volumes of distribution for vincristine, vinblastine, and vindesine were, respectively, 1.3, 1.5, and 1.9 l/kg body weight.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),[l] / [body·kg·weight],1.5,181227,DB00541,Vincristine
,6690071,apparent volumes of distribution,"The apparent volumes of distribution for vincristine, vinblastine, and vindesine were, respectively, 1.3, 1.5, and 1.9 l/kg body weight.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),[l] / [body·kg·weight],1.9,181228,DB00541,Vincristine
,6690071,total average excretion,"The total average excretion of the alkaloids over a 4-day period in urine and feces for vincristine, vinblastine, and vindesine were, respectively, 36.7%, 18.2%, and 25.3% of the injected dose.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),%,36.7,181229,DB00541,Vincristine
,6690071,total average excretion,"The total average excretion of the alkaloids over a 4-day period in urine and feces for vincristine, vinblastine, and vindesine were, respectively, 36.7%, 18.2%, and 25.3% of the injected dose.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),%,18.2,181230,DB00541,Vincristine
,6690071,total average excretion,"The total average excretion of the alkaloids over a 4-day period in urine and feces for vincristine, vinblastine, and vindesine were, respectively, 36.7%, 18.2%, and 25.3% of the injected dose.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),%,25.3,181231,DB00541,Vincristine
,3698163,Clearance,"Clearance was found to parallel toxicity for all drugs: it increases from 0.19 1 h-1 kg-1 for vincristine to 0.41 for Na-formyl navelbine, 1.4 for vinblastine, 2.3 for navelbine, and 2.6 for deacetyl navelbine amide.",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],0.19,181891,DB00541,Vincristine
,3698163,Clearance,"Clearance was found to parallel toxicity for all drugs: it increases from 0.19 1 h-1 kg-1 for vincristine to 0.41 for Na-formyl navelbine, 1.4 for vinblastine, 2.3 for navelbine, and 2.6 for deacetyl navelbine amide.",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],0.41,181892,DB00541,Vincristine
,3698163,Clearance,"Clearance was found to parallel toxicity for all drugs: it increases from 0.19 1 h-1 kg-1 for vincristine to 0.41 for Na-formyl navelbine, 1.4 for vinblastine, 2.3 for navelbine, and 2.6 for deacetyl navelbine amide.",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],1.4,181893,DB00541,Vincristine
,3698163,Clearance,"Clearance was found to parallel toxicity for all drugs: it increases from 0.19 1 h-1 kg-1 for vincristine to 0.41 for Na-formyl navelbine, 1.4 for vinblastine, 2.3 for navelbine, and 2.6 for deacetyl navelbine amide.",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],2.3,181894,DB00541,Vincristine
,3698163,Clearance,"Clearance was found to parallel toxicity for all drugs: it increases from 0.19 1 h-1 kg-1 for vincristine to 0.41 for Na-formyl navelbine, 1.4 for vinblastine, 2.3 for navelbine, and 2.6 for deacetyl navelbine amide.",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],2.6,181895,DB00541,Vincristine
,3698163,Terminal half-lives,Terminal half-lives were longer for the Na-formyl-substituted alkaloids (around 13 h) than for the others (8-10 h).,Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),h,13,181896,DB00541,Vincristine
,3698163,Terminal half-lives,Terminal half-lives were longer for the Na-formyl-substituted alkaloids (around 13 h) than for the others (8-10 h).,Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),h,8-10,181897,DB00541,Vincristine
,3698163,clearance,"We have also studied navelbine kinetics in cancer patients entered in recent navelbine clinical trials and found that navelbine pharmacokinetics are characterized by fast and extensive distribution, high clearance (0.92 +/- 0.27 1 h-1 kg-1), and a relatively long terminal half-life (31.2 +/- 4.4 h).",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],0.92,181898,DB00541,Vincristine
,3698163,terminal half-life,"We have also studied navelbine kinetics in cancer patients entered in recent navelbine clinical trials and found that navelbine pharmacokinetics are characterized by fast and extensive distribution, high clearance (0.92 +/- 0.27 1 h-1 kg-1), and a relatively long terminal half-life (31.2 +/- 4.4 h).",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),h,31.2,181899,DB00541,Vincristine
,7070351,terminal phase half-life,"However, vincristine had a longer and more variable terminal phase half-life (85 +/- 69 hr) than vindesine (24 +/- 10 hr) or vinblastine (25 +/- 7 hr).","The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7070351/),h,85,194070,DB00541,Vincristine
,7070351,terminal phase half-life,"However, vincristine had a longer and more variable terminal phase half-life (85 +/- 69 hr) than vindesine (24 +/- 10 hr) or vinblastine (25 +/- 7 hr).","The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7070351/),h,24,194071,DB00541,Vincristine
,7070351,terminal phase half-life,"However, vincristine had a longer and more variable terminal phase half-life (85 +/- 69 hr) than vindesine (24 +/- 10 hr) or vinblastine (25 +/- 7 hr).","The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7070351/),h,25,194072,DB00541,Vincristine
,7070351,serum,"The most important finding was the observation of differences in the serum or body clearances of these drugs (vincristine 0.106 liter/kg/hr, vindesine 0.252 liter/kg/hr, and vinblastine 0.740 liter/kg/hr).","The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7070351/),[l] / [h·kg],0.106,194073,DB00541,Vincristine
,7070351,body clearances,"The most important finding was the observation of differences in the serum or body clearances of these drugs (vincristine 0.106 liter/kg/hr, vindesine 0.252 liter/kg/hr, and vinblastine 0.740 liter/kg/hr).","The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7070351/),[l] / [h·kg],0.106,194074,DB00541,Vincristine
,7070351,body clearances,"The most important finding was the observation of differences in the serum or body clearances of these drugs (vincristine 0.106 liter/kg/hr, vindesine 0.252 liter/kg/hr, and vinblastine 0.740 liter/kg/hr).","The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7070351/),[l] / [h·kg],0.252,194075,DB00541,Vincristine
,7070351,body clearances,"The most important finding was the observation of differences in the serum or body clearances of these drugs (vincristine 0.106 liter/kg/hr, vindesine 0.252 liter/kg/hr, and vinblastine 0.740 liter/kg/hr).","The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7070351/),[l] / [h·kg],0.740,194076,DB00541,Vincristine
,10348715,half-lives,The respective half-lives of 3.3 and 2.1 days represent the lowest known clearance rates of proteases in circulating human plasma.,Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348715/),d,3.3,194733,DB00541,Vincristine
,10348715,half-lives,The respective half-lives of 3.3 and 2.1 days represent the lowest known clearance rates of proteases in circulating human plasma.,Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348715/),d,2.1,194734,DB00541,Vincristine
,25394095,concentration,Plasma concentrations of raltegravir in eight patients showed a median concentration of 143 ng/mL (79-455).,"Efficacy, safety, and lack of interactions with the use of raltegravir in HIV-infected patients undergoing antineoplastic chemotherapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25394095/),[ng] / [ml],143,195476,DB00541,Vincristine
,8877249,bioavailability,The bioavailability of a liquid filled gelatin capsule ranges between 12 and 59% with a mean value of 27% [standard deviation (SD) 12%].,Clinical pharmacokinetics of vinorelbine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),%,27,195585,DB00541,Vincristine
,8877249,unbound blood fraction,"In vitro, vinorelbine is mainly distributed into the blood cells, especially platelets (78%) and lymphocytes (4.8%) The unbound blood fraction is around 2%.",Clinical pharmacokinetics of vinorelbine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),%,2,195586,DB00541,Vincristine
,8877249,amount of radioactivity,"Faecal elimination has been demonstrated in 2 patients who were administered 3H-labelled vinorelbine; the amount of radioactivity recovered in the faeces was 33.9 and 58.4% for the 2 patients, respectively.",Clinical pharmacokinetics of vinorelbine. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),%,33.9,195587,DB00541,Vincristine
,8877249,amount of radioactivity,"Faecal elimination has been demonstrated in 2 patients who were administered 3H-labelled vinorelbine; the amount of radioactivity recovered in the faeces was 33.9 and 58.4% for the 2 patients, respectively.",Clinical pharmacokinetics of vinorelbine. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),%,58.4,195588,DB00541,Vincristine
,8877249,terminal half-life (t1/2),The pharmacokinetic profile of vinorelbine is often described as a 3-compartment model characterised by a long terminal half-life (t1/2) that varies between 20 and 40 hours and a large apparent volume of distribution (Vd) of around 70 L/kg.,Clinical pharmacokinetics of vinorelbine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),h,20 and 40,195589,DB00541,Vincristine
,8877249,apparent volume of distribution (Vd),The pharmacokinetic profile of vinorelbine is often described as a 3-compartment model characterised by a long terminal half-life (t1/2) that varies between 20 and 40 hours and a large apparent volume of distribution (Vd) of around 70 L/kg.,Clinical pharmacokinetics of vinorelbine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[l] / [kg],70,195590,DB00541,Vincristine
,8877249,Systemic clearance,Systemic clearance ranges between 72.54 and 89.46 L/h (1209 and 1491 ml/min) when determined by high performance liquid chromatography and is higher than that reported by radioimmunoassay [46.2 L/h (770 ml/min)].,Clinical pharmacokinetics of vinorelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[l] / [h],72.54 and 89.46,195591,DB00541,Vincristine
,8877249,Systemic clearance,Systemic clearance ranges between 72.54 and 89.46 L/h (1209 and 1491 ml/min) when determined by high performance liquid chromatography and is higher than that reported by radioimmunoassay [46.2 L/h (770 ml/min)].,Clinical pharmacokinetics of vinorelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[ml] / [min],1209 and 1491,195592,DB00541,Vincristine
,8877249,Systemic clearance,Systemic clearance ranges between 72.54 and 89.46 L/h (1209 and 1491 ml/min) when determined by high performance liquid chromatography and is higher than that reported by radioimmunoassay [46.2 L/h (770 ml/min)].,Clinical pharmacokinetics of vinorelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[l] / [h],46.2,195593,DB00541,Vincristine
,8877249,t1/2,"In children, vinorelbine seems to display a shorter t1/2 (14.7 hours) than that found in adults.",Clinical pharmacokinetics of vinorelbine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),h,14.7,195594,DB00541,Vincristine
,8877249,systemic clearance,"In addition, the systemic clearance is highly variable [from 12 to 93.96 L/h/m2 (200 to 1566 ml/min/m2)].",Clinical pharmacokinetics of vinorelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[l] / [h·m2],12 to 93.96,195595,DB00541,Vincristine
,8877249,systemic clearance,"In addition, the systemic clearance is highly variable [from 12 to 93.96 L/h/m2 (200 to 1566 ml/min/m2)].",Clinical pharmacokinetics of vinorelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[ml] / [m2·min],200 to 1566,195596,DB00541,Vincristine
,4016723,maximal tolerated dose,The maximal tolerated dose appears to be about 43 mg/m2.,Phase I pharmacologic study of a new Vinca alkaloid: navelbine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4016723/),[mg] / [m2],43,196957,DB00541,Vincristine
,4016723,elimination half-life,"Pharmacokinetics, studied with a radioimmunoassay (RIA) method, suggested an elimination half-life of 30 h and a plasma clearance of 75 l/h.",Phase I pharmacologic study of a new Vinca alkaloid: navelbine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4016723/),h,30,196958,DB00541,Vincristine
,4016723,plasma clearance,"Pharmacokinetics, studied with a radioimmunoassay (RIA) method, suggested an elimination half-life of 30 h and a plasma clearance of 75 l/h.",Phase I pharmacologic study of a new Vinca alkaloid: navelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4016723/),[l] / [h],75,196959,DB00541,Vincristine
,20042378,flow rate,"Chromatographic separation was achieved on a C8 HPLC column (Phenomenex Luna 50 mm x 2.0 mm, 3.0 microm) with a mobile phase gradient at a flow rate of 0.2 ml/min.",Validation of an electrospray ionization LC/MS/MS method for quantitative analysis of vincristine in human plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20042378/),[ml] / [min],0.2,197044,DB00541,Vincristine
,23658485,particle,"The mean particle size, zeta potential, and encapsulation efficiency were 157.6 ± 12.6 nm, -26.5 ± 5.0 mV and 78.64% ± 3.44%, respectively.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),nm,157.6,198765,DB00541,Vincristine
,23658485,zeta potential,"The mean particle size, zeta potential, and encapsulation efficiency were 157.6 ± 12.6 nm, -26.5 ± 5.0 mV and 78.64% ± 3.44%, respectively.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),m,-,198766,DB00541,Vincristine
,23658485,zeta potential,"The mean particle size, zeta potential, and encapsulation efficiency were 157.6 ± 12.6 nm, -26.5 ± 5.0 mV and 78.64% ± 3.44%, respectively.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),m,26.5,198767,DB00541,Vincristine
,23658485,encapsulation efficiency,"The mean particle size, zeta potential, and encapsulation efficiency were 157.6 ± 12.6 nm, -26.5 ± 5.0 mV and 78.64% ± 3.44%, respectively.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),m,26.5,198768,DB00541,Vincristine
,23658485,encapsulation efficiency,"The mean particle size, zeta potential, and encapsulation efficiency were 157.6 ± 12.6 nm, -26.5 ± 5.0 mV and 78.64% ± 3.44%, respectively.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),%,78.64,198769,DB00541,Vincristine
,23658485,mean residence time [0-∞],"Compared with VCR solution, the pharmacokinetic study of VCR-OA-SME showed relatively longer mean residence time (mean residence time [0-∞] increased from 187.19 to 227.56 minutes), higher maximum concentration (from 252.13 ng/mL to 533.34 ng/mL), and greater area under the curve (area under the curve [0-∞] from 11,417.77 μg/L/minute to 17,164.34 μg/L/minute.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),min,187.19,198770,DB00541,Vincristine
,23658485,mean residence time [0-∞],"Compared with VCR solution, the pharmacokinetic study of VCR-OA-SME showed relatively longer mean residence time (mean residence time [0-∞] increased from 187.19 to 227.56 minutes), higher maximum concentration (from 252.13 ng/mL to 533.34 ng/mL), and greater area under the curve (area under the curve [0-∞] from 11,417.77 μg/L/minute to 17,164.34 μg/L/minute.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),min,227,198771,DB00541,Vincristine
,23658485,maximum concentration,"Compared with VCR solution, the pharmacokinetic study of VCR-OA-SME showed relatively longer mean residence time (mean residence time [0-∞] increased from 187.19 to 227.56 minutes), higher maximum concentration (from 252.13 ng/mL to 533.34 ng/mL), and greater area under the curve (area under the curve [0-∞] from 11,417.77 μg/L/minute to 17,164.34 μg/L/minute.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),[ng] / [ml],252.13,198772,DB00541,Vincristine
,23658485,maximum concentration,"Compared with VCR solution, the pharmacokinetic study of VCR-OA-SME showed relatively longer mean residence time (mean residence time [0-∞] increased from 187.19 to 227.56 minutes), higher maximum concentration (from 252.13 ng/mL to 533.34 ng/mL), and greater area under the curve (area under the curve [0-∞] from 11,417.77 μg/L/minute to 17,164.34 μg/L/minute.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),[ng] / [ml],533.34,198773,DB00541,Vincristine
,23658485,area under the curve (area under the curve [0-∞],"Compared with VCR solution, the pharmacokinetic study of VCR-OA-SME showed relatively longer mean residence time (mean residence time [0-∞] increased from 187.19 to 227.56 minutes), higher maximum concentration (from 252.13 ng/mL to 533.34 ng/mL), and greater area under the curve (area under the curve [0-∞] from 11,417.77 μg/L/minute to 17,164.34 μg/L/minute.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),[μg] / [l·min],"11,417.77",198774,DB00541,Vincristine
,23658485,area under the curve (area under the curve [0-∞],"Compared with VCR solution, the pharmacokinetic study of VCR-OA-SME showed relatively longer mean residence time (mean residence time [0-∞] increased from 187.19 to 227.56 minutes), higher maximum concentration (from 252.13 ng/mL to 533.34 ng/mL), and greater area under the curve (area under the curve [0-∞] from 11,417.77 μg/L/minute to 17,164.34 μg/L/minute.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),[μg] / [l·min],"17,164.34",198775,DB00541,Vincristine
,27329361,volume of distribution of central compartment,"The volume of distribution of central compartment and clearance of Reditux™ were estimated at 0.95 L and 5.98 mL/h, respectively.","Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27329361/),l,0.95,200467,DB00541,Vincristine
,27329361,clearance of Reditux™,"The volume of distribution of central compartment and clearance of Reditux™ were estimated at 0.95 L and 5.98 mL/h, respectively.","Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27329361/),[ml] / [h],5.98,200468,DB00541,Vincristine
,25649934,volume of distribution,"The volume of distribution, distribution half-life, elimination half-life and plasma clearance were 0.660 ± 0.210 l/kg, 21.5 ± 6.90 min, 47.6 ± 14.2 min and 0.010 ± 0.001 l/min/kg, respectively.",Clinical pharmacokinetics and effects of vincristine sulfate in dogs with transmissible venereal tumor (TVT). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25649934/),[l] / [kg],0.660,200473,DB00541,Vincristine
,25649934,elimination half-life,"The volume of distribution, distribution half-life, elimination half-life and plasma clearance were 0.660 ± 0.210 l/kg, 21.5 ± 6.90 min, 47.6 ± 14.2 min and 0.010 ± 0.001 l/min/kg, respectively.",Clinical pharmacokinetics and effects of vincristine sulfate in dogs with transmissible venereal tumor (TVT). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25649934/),min,21.5,200474,DB00541,Vincristine
,25649934,elimination half-life,"The volume of distribution, distribution half-life, elimination half-life and plasma clearance were 0.660 ± 0.210 l/kg, 21.5 ± 6.90 min, 47.6 ± 14.2 min and 0.010 ± 0.001 l/min/kg, respectively.",Clinical pharmacokinetics and effects of vincristine sulfate in dogs with transmissible venereal tumor (TVT). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25649934/),min,47.6,200475,DB00541,Vincristine
,25649934,plasma clearance,"The volume of distribution, distribution half-life, elimination half-life and plasma clearance were 0.660 ± 0.210 l/kg, 21.5 ± 6.90 min, 47.6 ± 14.2 min and 0.010 ± 0.001 l/min/kg, respectively.",Clinical pharmacokinetics and effects of vincristine sulfate in dogs with transmissible venereal tumor (TVT). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25649934/),[l] / [kg·min],0.010,200476,DB00541,Vincristine
,27154915,overall response rate (ORR),"Among patients receiving the MTD (n = 38), the overall response rate (ORR) was 84% (n = 32), including 24% (n = 9) with complete response; the ORR was 100% for patients with indolent lymphoma (n = 27) and 57% for those with aggressive histology lymphoma (n = 21).",Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154915/),%,84,202921,DB00541,Vincristine
,27154915,overall response rate (ORR),"Among patients receiving the MTD (n = 38), the overall response rate (ORR) was 84% (n = 32), including 24% (n = 9) with complete response; the ORR was 100% for patients with indolent lymphoma (n = 27) and 57% for those with aggressive histology lymphoma (n = 21).",Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154915/),%,24,202922,DB00541,Vincristine
,27154915,ORR,"Among patients receiving the MTD (n = 38), the overall response rate (ORR) was 84% (n = 32), including 24% (n = 9) with complete response; the ORR was 100% for patients with indolent lymphoma (n = 27) and 57% for those with aggressive histology lymphoma (n = 21).",Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154915/),,100,202923,DB00541,Vincristine
,27154915,ORR,"Among patients receiving the MTD (n = 38), the overall response rate (ORR) was 84% (n = 32), including 24% (n = 9) with complete response; the ORR was 100% for patients with indolent lymphoma (n = 27) and 57% for those with aggressive histology lymphoma (n = 21).",Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154915/),,57,202924,DB00541,Vincristine
,9747681,peak vitreous concentration,"Mean measured peak vitreous concentration of carboplatin after intravenous administration was 0.31 microg/mL, which was 1% of the peak plasma value.",Intraocular concentrations of chemotherapeutic agents after systemic or local administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9747681/),[μg] / [ml],0.31,203792,DB00541,Vincristine
,9747681,peak vitreous concentrations,"Mean measured peak vitreous concentrations of carboplatin after peribulbar or episcleral balloon administration were 2.38 microg/mL and 2.95 microg/mL, respectively, which represent 7.68- and 9.52-fold increases over the concentration achieved after intravenous administration.",Intraocular concentrations of chemotherapeutic agents after systemic or local administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9747681/),[μg] / [ml],2.38,203793,DB00541,Vincristine
,9747681,peak vitreous concentrations,"Mean measured peak vitreous concentrations of carboplatin after peribulbar or episcleral balloon administration were 2.38 microg/mL and 2.95 microg/mL, respectively, which represent 7.68- and 9.52-fold increases over the concentration achieved after intravenous administration.",Intraocular concentrations of chemotherapeutic agents after systemic or local administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9747681/),[μg] / [ml],2.95,203794,DB00541,Vincristine
,872088,t1/2 alpha,"The kinetic parameters included: t1/2 alpha=3.24+/-1.14 min, t1/2beta=99.0+/-44.5 min, t1/2gamma=1213+/-493 min, Vc (Valpha)=4.81+/-2.12 liters, Vbeta=58.2+/-50.5 liters, Vgamma=598+/-294 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),min,3.24,204345,DB00541,Vincristine
,872088,t1/2beta,"The kinetic parameters included: t1/2 alpha=3.24+/-1.14 min, t1/2beta=99.0+/-44.5 min, t1/2gamma=1213+/-493 min, Vc (Valpha)=4.81+/-2.12 liters, Vbeta=58.2+/-50.5 liters, Vgamma=598+/-294 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),min,99.0,204346,DB00541,Vincristine
,872088,t1/2gamma,"The kinetic parameters included: t1/2 alpha=3.24+/-1.14 min, t1/2beta=99.0+/-44.5 min, t1/2gamma=1213+/-493 min, Vc (Valpha)=4.81+/-2.12 liters, Vbeta=58.2+/-50.5 liters, Vgamma=598+/-294 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),min,1213,204347,DB00541,Vincristine
,872088,Vc (Valpha),"The kinetic parameters included: t1/2 alpha=3.24+/-1.14 min, t1/2beta=99.0+/-44.5 min, t1/2gamma=1213+/-493 min, Vc (Valpha)=4.81+/-2.12 liters, Vbeta=58.2+/-50.5 liters, Vgamma=598+/-294 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),l,4.81,204348,DB00541,Vincristine
,872088,Vbeta,"The kinetic parameters included: t1/2 alpha=3.24+/-1.14 min, t1/2beta=99.0+/-44.5 min, t1/2gamma=1213+/-493 min, Vc (Valpha)=4.81+/-2.12 liters, Vbeta=58.2+/-50.5 liters, Vgamma=598+/-294 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),l,58.2,204349,DB00541,Vincristine
,872088,Vgamma,"The kinetic parameters included: t1/2 alpha=3.24+/-1.14 min, t1/2beta=99.0+/-44.5 min, t1/2gamma=1213+/-493 min, Vc (Valpha)=4.81+/-2.12 liters, Vbeta=58.2+/-50.5 liters, Vgamma=598+/-294 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),l,598,204350,DB00541,Vincristine
,872088,t1/2 alpha,"Vincristine, studied only for the first 4 hr, behaved like a two-compartment system, with values of t1/2 alpha=3.37+/-0.72 min, t1/2beta=155+/-18 min, Valpha=4.53+/-0.49 liters, and Vbeta=57.3+/-21.1 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),min,3.37,204351,DB00541,Vincristine
,872088,t1/2beta,"Vincristine, studied only for the first 4 hr, behaved like a two-compartment system, with values of t1/2 alpha=3.37+/-0.72 min, t1/2beta=155+/-18 min, Valpha=4.53+/-0.49 liters, and Vbeta=57.3+/-21.1 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),min,155,204352,DB00541,Vincristine
,872088,Valpha,"Vincristine, studied only for the first 4 hr, behaved like a two-compartment system, with values of t1/2 alpha=3.37+/-0.72 min, t1/2beta=155+/-18 min, Valpha=4.53+/-0.49 liters, and Vbeta=57.3+/-21.1 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),l,4.53,204353,DB00541,Vincristine
,872088,Vbeta,"Vincristine, studied only for the first 4 hr, behaved like a two-compartment system, with values of t1/2 alpha=3.37+/-0.72 min, t1/2beta=155+/-18 min, Valpha=4.53+/-0.49 liters, and Vbeta=57.3+/-21.1 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),l,57.3,204354,DB00541,Vincristine
,20555126,Trough levels,"Trough levels of 4 patients on three-monthly schedule maintenance therapy remained constant, with a median concentration of 6 mu g/mL (range 0.5-11.7 microg/mL).",Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20555126/),[g·mu] / [ml],6,204913,DB00541,Vincristine
,20555126,elimination half-life at steady state,"The elimination half-life at steady state of rituximab in all patients was estimated to be 19.2 (+/- 15.2%) days with a between-subject variability of 54%, indicating wide variability.",Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20555126/),d,19.2,204914,DB00541,Vincristine
,23762298,volume of distribution,"Pharmacokinetic studies showed that, as with other species, there was a rapid drop in blood concentration following a rapid intravenous infusion with a high volume of distribution (1.96 L/kg) and a relatively long elimination half life (11 h).",Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23762298/),[l] / [kg],1.96,214863,DB00541,Vincristine
,23762298,elimination half life,"Pharmacokinetic studies showed that, as with other species, there was a rapid drop in blood concentration following a rapid intravenous infusion with a high volume of distribution (1.96 L/kg) and a relatively long elimination half life (11 h).",Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23762298/),h,11,214864,DB00541,Vincristine
,23762298,Plasma clearance,"Plasma clearance (1.8 ml/min/kg) was slower in the Tasmanian devil than in humans, suggesting that pharmacodynamics and not pharmacokinetics explain the Tasmanian devil's ability to tolerate high dosage rates of vincristine.",Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23762298/),[ml] / [kg·min],1.8,214865,DB00541,Vincristine
,17290615,release time,The release time of VCR from compound liposome was 24 h and that from free drug (in control solution) was 6 h.,[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,24,215174,DB00541,Vincristine
,17290615,release time,The release time of VCR from compound liposome was 24 h and that from free drug (in control solution) was 6 h.,[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,6,215175,DB00541,Vincristine
,17290615,release time,The release of MTO from compound liposome was 0.05% after 288 h and release time of MTO from free drug (in control solution) was 12 h.,[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,12,215176,DB00541,Vincristine
,17290615,elimination half-life time (T 1/2),"The elimination half-life time (T 1/2) in plasma of liposomal and free VCR were 0.16 h and 0.14 h, and the AUCs (0 - 48 h) of them were 2.69 (ug x g(-1)) x h and 1.58 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,0.16,215177,DB00541,Vincristine
,17290615,elimination half-life time (T 1/2),"The elimination half-life time (T 1/2) in plasma of liposomal and free VCR were 0.16 h and 0.14 h, and the AUCs (0 - 48 h) of them were 2.69 (ug x g(-1)) x h and 1.58 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,0.14,215178,DB00541,Vincristine
,17290615,AUCs (0 - 48 h),"The elimination half-life time (T 1/2) in plasma of liposomal and free VCR were 0.16 h and 0.14 h, and the AUCs (0 - 48 h) of them were 2.69 (ug x g(-1)) x h and 1.58 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),[h·ug] / [g],2.69,215179,DB00541,Vincristine
,17290615,AUCs (0 - 48 h),"The elimination half-life time (T 1/2) in plasma of liposomal and free VCR were 0.16 h and 0.14 h, and the AUCs (0 - 48 h) of them were 2.69 (ug x g(-1)) x h and 1.58 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),[h·ug] / [g],1.58,215180,DB00541,Vincristine
,17290615,elimination half-life times (T 1/2),"The elimination half-life times (T 1/2) in plasma of liposomal and free MTO were 21.6 h and 0.05 h and the AUCs (0 - 48 h) of them were 17.06 (ug x g(-1)) x h and 0.42 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,21.6,215181,DB00541,Vincristine
,17290615,elimination half-life times (T 1/2),"The elimination half-life times (T 1/2) in plasma of liposomal and free MTO were 21.6 h and 0.05 h and the AUCs (0 - 48 h) of them were 17.06 (ug x g(-1)) x h and 0.42 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,0.05,215182,DB00541,Vincristine
,17290615,AUCs (0 - 48 h),"The elimination half-life times (T 1/2) in plasma of liposomal and free MTO were 21.6 h and 0.05 h and the AUCs (0 - 48 h) of them were 17.06 (ug x g(-1)) x h and 0.42 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),[h·ug] / [g],17.06,215183,DB00541,Vincristine
,17290615,AUCs (0 - 48 h),"The elimination half-life times (T 1/2) in plasma of liposomal and free MTO were 21.6 h and 0.05 h and the AUCs (0 - 48 h) of them were 17.06 (ug x g(-1)) x h and 0.42 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),[h·ug] / [g],0.42,215184,DB00541,Vincristine
,21968951,plasma,"Vincristine plasma and intracellular concentrations ranged from 0.40 to 89.6 ng/ml and from 0.00225 to 1.85 ng/10(6) cells over a 24-h interval, respectively.","Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21968951/),[ng] / [ml],0.40 to 89.6,216077,DB00541,Vincristine
,21968951,intracellular concentrations,"Vincristine plasma and intracellular concentrations ranged from 0.40 to 89.6 ng/ml and from 0.00225 to 1.85 ng/10(6) cells over a 24-h interval, respectively.","Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21968951/),[ng] / [10],0.00225 to 1.85,216078,DB00541,Vincristine
,8339259,"dissociation constant, Kd","The gamma-emitting probe used in the RIA, 125I-(deacetyl-O4-vinblastine)-tyramine, bound very tightly to the monoclonal antibody (dissociation constant, Kd = 2.5 x 10(-11) M), demonstrating a high affinity mainly directed toward the catharantine nucleus (vindesine, vincristine, vinblastine, 100% cross-reactivity; vinorelbine, 0.3% cross-reactivity).",Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339259/),M,2.5 x 10(-11),222912,DB00541,Vincristine
,8339259,terminal half-life; t1/2 gamma,"As determined by RIA, the S 12363 plasma profile was triphasic with a terminal half-life; t1/2 gamma = 49 +/- 16 h, a plasma clearance, CL = 0.14 +/- 0.04 liter/h/kg, and a volume of distribution at steady state, Vdss = 5.0 +/- 2.8 liter/kg.",Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339259/),h,49,222913,DB00541,Vincristine
,8339259,"plasma clearance, CL","As determined by RIA, the S 12363 plasma profile was triphasic with a terminal half-life; t1/2 gamma = 49 +/- 16 h, a plasma clearance, CL = 0.14 +/- 0.04 liter/h/kg, and a volume of distribution at steady state, Vdss = 5.0 +/- 2.8 liter/kg.",Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339259/),[l] / [h·kg],0.14,222914,DB00541,Vincristine
,8339259,"volume of distribution at steady state, Vdss","As determined by RIA, the S 12363 plasma profile was triphasic with a terminal half-life; t1/2 gamma = 49 +/- 16 h, a plasma clearance, CL = 0.14 +/- 0.04 liter/h/kg, and a volume of distribution at steady state, Vdss = 5.0 +/- 2.8 liter/kg.",Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339259/),[l] / [kg],5.0,222915,DB00541,Vincristine
,21699456,AUC,"There was substantial inter-individual variability in MTX AUC (median: 795.5 µM*h/L, range 44.8-8326.44).",Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21699456/),[h·μM] / [l],795.5,224886,DB00541,Vincristine
,20083201,"t(1/2,beta)","However, the t(1/2,beta) and t(1/2,gamma) were shorter in the obese mice (9.7 min vs. 44.5 min and 60.3h vs. 85.6h, respectively), resulting in a lower AUC(0-infinity) (13,099 ng/m Lh vs. 15,384 ng/mL h).",Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20083201/),min,9.7,225094,DB00541,Vincristine
,20083201,"t(1/2,beta)","However, the t(1/2,beta) and t(1/2,gamma) were shorter in the obese mice (9.7 min vs. 44.5 min and 60.3h vs. 85.6h, respectively), resulting in a lower AUC(0-infinity) (13,099 ng/m Lh vs. 15,384 ng/mL h).",Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20083201/),min,44.5,225095,DB00541,Vincristine
,20083201,"t(1/2,gamma)","However, the t(1/2,beta) and t(1/2,gamma) were shorter in the obese mice (9.7 min vs. 44.5 min and 60.3h vs. 85.6h, respectively), resulting in a lower AUC(0-infinity) (13,099 ng/m Lh vs. 15,384 ng/mL h).",Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20083201/),h,60.3,225096,DB00541,Vincristine
,20083201,"t(1/2,gamma)","However, the t(1/2,beta) and t(1/2,gamma) were shorter in the obese mice (9.7 min vs. 44.5 min and 60.3h vs. 85.6h, respectively), resulting in a lower AUC(0-infinity) (13,099 ng/m Lh vs. 15,384 ng/mL h).",Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20083201/),h,85.6,225097,DB00541,Vincristine
,20083201,AUC(0-infinity),"However, the t(1/2,beta) and t(1/2,gamma) were shorter in the obese mice (9.7 min vs. 44.5 min and 60.3h vs. 85.6h, respectively), resulting in a lower AUC(0-infinity) (13,099 ng/m Lh vs. 15,384 ng/mL h).",Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20083201/),[ng] / [lh·m],"13,099",225098,DB00541,Vincristine
,20083201,AUC(0-infinity),"However, the t(1/2,beta) and t(1/2,gamma) were shorter in the obese mice (9.7 min vs. 44.5 min and 60.3h vs. 85.6h, respectively), resulting in a lower AUC(0-infinity) (13,099 ng/m Lh vs. 15,384 ng/mL h).",Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20083201/),[ng] / [h·ml],"15,384",225099,DB00541,Vincristine
,23802738,overall response rate,The overall response rate was 96% (69/72) including complete response (CR) in 65 (90%) and unconfirmed CR in 2 (3%).,"Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802738/),%,96,226475,DB00541,Vincristine
,15728147,AUC(0-8),"When indinavir was given concomitantly with CHOP, the AUC(0-8) increased by 38% (20.5 +/- 9.0 versus 14.9 +/- 9.5 mg.h/L; P=0.03), and was comparable to historical controls.",Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728147/),[h·mg] / [l],20.5,227142,DB00541,Vincristine
,15728147,AUC(0-8),"When indinavir was given concomitantly with CHOP, the AUC(0-8) increased by 38% (20.5 +/- 9.0 versus 14.9 +/- 9.5 mg.h/L; P=0.03), and was comparable to historical controls.",Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728147/),[h·mg] / [l],14.9,227143,DB00541,Vincristine
,15728147,IC(50),"Likewise, we observed a significant number of patients with C(0) and C(8) below the IC(50) for the wild-type virus (0.1 mg/L) when the drug was administered without CHOP.",Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728147/),[mg] / [l],0.1,227144,DB00541,Vincristine
,6260340,terminal half-life,"Despite a prolonged terminal half-life of vincristine in the serum (14.4 to 37.5 hr) following i.v. bolus injection, concentrations of vincristine in the CSF ranged between undetectable within the limits of the assay and 1.1 X 10(-9) M during the 24-hr period of observation.",Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6260340/),h,14.4 to 37.5,230364,DB00541,Vincristine
,24828449,flow rate,The flow rate was set at 0.4 mL/min.,Liquid chromatography mass spectrometry simultaneous determination of vindoline and catharanthine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24828449/),[ml] / [min],0.4,231005,DB00541,Vincristine
,24828449,recoveries,Mean recoveries were in the range of 87.3-92.6% for vindoline in rat plasma and 88.5-96.5% for catharanthine.,Liquid chromatography mass spectrometry simultaneous determination of vindoline and catharanthine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24828449/),%,87.3-92.6,231006,DB00541,Vincristine
,24828449,recoveries,Mean recoveries were in the range of 87.3-92.6% for vindoline in rat plasma and 88.5-96.5% for catharanthine.,Liquid chromatography mass spectrometry simultaneous determination of vindoline and catharanthine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24828449/),%,88.5-96.5,231007,DB00541,Vincristine
,24828449,Matrix effects,Matrix effects for vindoline and catharanthine were measured to be between 95.3 and 104.7%.,Liquid chromatography mass spectrometry simultaneous determination of vindoline and catharanthine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24828449/),%,95.3 and 104.7,231008,DB00541,Vincristine
,24828449,bioavailability,"The bioavailability of vindoline and catharanthine were 5.4 and 4.7%, respectively.",Liquid chromatography mass spectrometry simultaneous determination of vindoline and catharanthine in rat plasma and its application to a pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24828449/),%,5.4,231009,DB00541,Vincristine
,24828449,bioavailability,"The bioavailability of vindoline and catharanthine were 5.4 and 4.7%, respectively.",Liquid chromatography mass spectrometry simultaneous determination of vindoline and catharanthine in rat plasma and its application to a pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24828449/),%,4.7,231010,DB00541,Vincristine
,10613614,systemic clearance,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),[ml] / [min],925,231628,DB00541,Vincristine
,10613614,systemic clearance,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),[ml] / [min],569,231629,DB00541,Vincristine
,10613614,elimination half-life,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),h,12.7,231630,DB00541,Vincristine
,10613614,elimination half-life,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),h,19.4,231631,DB00541,Vincristine
,10613614,total area under the plasma concentration-time curve,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),[h·ng] / [ml],37.3,231632,DB00541,Vincristine
,10613614,total area under the plasma concentration-time curve,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),[h·ng] / [ml],65.1,231633,DB00541,Vincristine
,10972486,peak value,"Intravenous administration of CHG(Et)2 resulted in the rapid appearance of CHG(Et)2 in the plasma of tumor-bearing mice with a peak value of 40-60 microM, followed by a first-order decrease with a half-life of about 10 min.",Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972486/),μM,40-60,234017,DB00541,Vincristine
,10972486,half-life,"Intravenous administration of CHG(Et)2 resulted in the rapid appearance of CHG(Et)2 in the plasma of tumor-bearing mice with a peak value of 40-60 microM, followed by a first-order decrease with a half-life of about 10 min.",Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972486/),min,10,234018,DB00541,Vincristine
,10972486,maximum concentration,"There was a corresponding increase in the concentration of inhibitory CHG in the B16 tumors, with a maximum concentration in the range 30-60 microM occurring at 15 min, followed by a decrease to a plateau value of about 6 microM after 120 min.",Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972486/),μM,30-60,234019,DB00541,Vincristine
,10972486,maximum concentration,"There was a corresponding increase in the concentration of inhibitory CHG in the B16 tumors, with a maximum concentration in the range 30-60 microM occurring at 15 min, followed by a decrease to a plateau value of about 6 microM after 120 min.",Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972486/),,6,234020,DB00541,Vincristine
,15315776,extraction recoveries,"The extraction recoveries of vincristine were 57 and 60% from plasma and brain tissues, respectively.",Determination of vincristine in mouse plasma and brain tissues by liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315776/),%,57,234128,DB00541,Vincristine
,15315776,extraction recoveries,"The extraction recoveries of vincristine were 57 and 60% from plasma and brain tissues, respectively.",Determination of vincristine in mouse plasma and brain tissues by liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315776/),%,60,234129,DB00541,Vincristine
,15315776,retention times,"The mobile phase consisted of methanol and 15 mM ammonium acetate in 0.02% formic acid (70:30) that was pumped at 0.2 ml/min to yield retention times of 1.6 and 1.8 min for vincristine and vinblastine, the internal standard, respectively.",Determination of vincristine in mouse plasma and brain tissues by liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315776/),min,1.6,234130,DB00541,Vincristine
,15315776,retention times,"The mobile phase consisted of methanol and 15 mM ammonium acetate in 0.02% formic acid (70:30) that was pumped at 0.2 ml/min to yield retention times of 1.6 and 1.8 min for vincristine and vinblastine, the internal standard, respectively.",Determination of vincristine in mouse plasma and brain tissues by liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315776/),min,1.8,234131,DB00541,Vincristine
> or =,14692520,time to absolute neutrophil count (ANC) recovery,"The pharmacokinetics of pegfilgrastim were characterized and the duration of grade 4 neutropenia, time to absolute neutrophil count (ANC) recovery to > or = 2.0 x 10(9)/l, neutrophil nadir, and incidence of febrile neutropenia were determined in the first 21-day chemotherapy cycle.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),,2.0 x 10(9),234938,DB00541,Vincristine
,14692520,duration of grade 4 neutropenia,The incidence of grade 4 neutropenia in cycle 1 was 43% with a mean (SD) duration of grade 4 neutropenia value of 1.0 (1.4) day.,Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),d,1.0,234939,DB00541,Vincristine
,14692520,time to ANC recovery,"The median [quartiles] time to ANC recovery was 10 [9, 11] days.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),d,10,234940,DB00541,Vincristine
,14692520,terminal half-life,"After the second peak, concentration of pegfilgrastim declined linearly with a median terminal half-life of approximately 42 h.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),h,42,234941,DB00541,Vincristine
,1714790,volume of distribution at steady-state,"For this patient, both the volume of distribution at steady-state (0.398 l/kg) and systemic clearance (0.0956 l/h/kg) of methotrexate were increased compared with values observed in adult patients with osteosarcoma.",Disposition of high-dose methotrexate in an obese cancer patient. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),[l] / [kg],0.398,242987,DB00541,Vincristine
,1714790,systemic clearance,"For this patient, both the volume of distribution at steady-state (0.398 l/kg) and systemic clearance (0.0956 l/h/kg) of methotrexate were increased compared with values observed in adult patients with osteosarcoma.",Disposition of high-dose methotrexate in an obese cancer patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),[l] / [h·kg],0.0956,242988,DB00541,Vincristine
,1714790,terminal elimination half-life,"The terminal elimination half-life (9.29 hours) of methotrexate was similar to other reported values in adult patients, thus indicating that increases in methotrexate volume of distribution and clearance may offset each other in obesity.",Disposition of high-dose methotrexate in an obese cancer patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),h,9.29,242989,DB00541,Vincristine
,8387903,clearance,Four patients with impaired liver function showed a significant (p < 0.05) decrease in clearance (239 versus 666 ml/min/m2) and increases in AUC (4610 versus 1834 ng.hr/ml) and elimination half-life (49.3 versus 25.6 hours) compared with patients with normal hepatic function.,Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8387903/),[ml] / [m2·min],239,243504,DB00541,Vincristine
,8387903,clearance,Four patients with impaired liver function showed a significant (p < 0.05) decrease in clearance (239 versus 666 ml/min/m2) and increases in AUC (4610 versus 1834 ng.hr/ml) and elimination half-life (49.3 versus 25.6 hours) compared with patients with normal hepatic function.,Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8387903/),[ml] / [m2·min],666,243505,DB00541,Vincristine
,8387903,AUC,Four patients with impaired liver function showed a significant (p < 0.05) decrease in clearance (239 versus 666 ml/min/m2) and increases in AUC (4610 versus 1834 ng.hr/ml) and elimination half-life (49.3 versus 25.6 hours) compared with patients with normal hepatic function.,Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8387903/),[h·ng] / [ml],4610,243506,DB00541,Vincristine
,8387903,AUC,Four patients with impaired liver function showed a significant (p < 0.05) decrease in clearance (239 versus 666 ml/min/m2) and increases in AUC (4610 versus 1834 ng.hr/ml) and elimination half-life (49.3 versus 25.6 hours) compared with patients with normal hepatic function.,Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8387903/),[h·ng] / [ml],1834,243507,DB00541,Vincristine
,8387903,elimination half-life,Four patients with impaired liver function showed a significant (p < 0.05) decrease in clearance (239 versus 666 ml/min/m2) and increases in AUC (4610 versus 1834 ng.hr/ml) and elimination half-life (49.3 versus 25.6 hours) compared with patients with normal hepatic function.,Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8387903/),h,49.3,243508,DB00541,Vincristine
,8387903,elimination half-life,Four patients with impaired liver function showed a significant (p < 0.05) decrease in clearance (239 versus 666 ml/min/m2) and increases in AUC (4610 versus 1834 ng.hr/ml) and elimination half-life (49.3 versus 25.6 hours) compared with patients with normal hepatic function.,Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8387903/),h,25.6,243509,DB00541,Vincristine
,18318429,area under the concentration-time curve,"The median (range) topotecan lactone area under the concentration-time curve after the first dose was 85.4 L/hour/m(2) (range, 38.7-229.3 L/hour/m(2)).","Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18318429/),[h·l] / [m(2],85.4,246782,DB00541,Vincristine
,17132721,peak serum concentration,"The population mean peak serum concentration of asparaginase enzymatic activity was 1 IU/mL, the elimination half-life was 7 days, and the volume of distribution was 2.43 L/m2.",Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132721/),[iu] / [ml],1,247719,DB00541,Vincristine
,17132721,elimination half-life,"The population mean peak serum concentration of asparaginase enzymatic activity was 1 IU/mL, the elimination half-life was 7 days, and the volume of distribution was 2.43 L/m2.",Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132721/),d,7,247720,DB00541,Vincristine
,17132721,volume of distribution,"The population mean peak serum concentration of asparaginase enzymatic activity was 1 IU/mL, the elimination half-life was 7 days, and the volume of distribution was 2.43 L/m2.",Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132721/),[l] / [m2],2.43,247721,DB00541,Vincristine
,17132721,enzymatic activity,A pharmocodynamic correlation model showed minimal enzymatic activity of 0.2 IU/mL for optimal asparagine depletion.,Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132721/),[iu] / [ml],0.2,247722,DB00541,Vincristine
,3359064,total plasma clearance,"Following IV bolus injection, the mean pharmacokinetic parameters are: total plasma clearance: 0.53 l/h-1kg-1, 0.72 l/h-1kg-1 and apparent elimination half-life: 23.2 h, 39.5 h for VDS and NVB, respectively.",[Clinical pharmacokinetics of vinca alkaloids]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3359064/),[l] / [h],0.53,249772,DB00541,Vincristine
,3359064,total plasma clearance,"Following IV bolus injection, the mean pharmacokinetic parameters are: total plasma clearance: 0.53 l/h-1kg-1, 0.72 l/h-1kg-1 and apparent elimination half-life: 23.2 h, 39.5 h for VDS and NVB, respectively.",[Clinical pharmacokinetics of vinca alkaloids]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3359064/),[l] / [h],0.72,249773,DB00541,Vincristine
,3359064,apparent elimination half-life,"Following IV bolus injection, the mean pharmacokinetic parameters are: total plasma clearance: 0.53 l/h-1kg-1, 0.72 l/h-1kg-1 and apparent elimination half-life: 23.2 h, 39.5 h for VDS and NVB, respectively.",[Clinical pharmacokinetics of vinca alkaloids]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3359064/),h,23.2,249774,DB00541,Vincristine
,3359064,apparent elimination half-life,"Following IV bolus injection, the mean pharmacokinetic parameters are: total plasma clearance: 0.53 l/h-1kg-1, 0.72 l/h-1kg-1 and apparent elimination half-life: 23.2 h, 39.5 h for VDS and NVB, respectively.",[Clinical pharmacokinetics of vinca alkaloids]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3359064/),h,39.5,249775,DB00541,Vincristine
,1688516,major response rate (CR + MR),The major response rate (CR + MR) was thus 35%.,A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688516/),%,35,250050,DB00541,Vincristine
,27616886,EE%,"However, the EE% was ~99.0% with drug loading at 2.0 mg/mL, which did not change after the coating process.",The influence of different long-circulating materials on the pharmacokinetics of liposomal vincristine sulfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27616886/),%,99.0,252974,DB00541,Vincristine
,24521993,Ctrough,"Geometric mean Ctrough was 83·13 μg/mL in the intravenous group and 134·58 μg/mL in the subcutaneous group (ratio 1·62, 90% CI 1·36-1·94), showing non-inferiority of subcutaneous rituximab.",Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521993/),[μg] / [ml],83·13,253189,DB00541,Vincristine
,24521993,Ctrough,"Geometric mean Ctrough was 83·13 μg/mL in the intravenous group and 134·58 μg/mL in the subcutaneous group (ratio 1·62, 90% CI 1·36-1·94), showing non-inferiority of subcutaneous rituximab.",Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521993/),[μg] / [ml],134·58,253190,DB00541,Vincristine
,11488768,Ki,"Vinblastine, vincristine and amsacrine at 500 microM significantly (P < 0.05) inhibited DMXAA glucuronidation (Ki = 319, 350 and 230 microM, respectively), but not 6-methylhydroxylation in human liver microsomes.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,319,255424,DB00541,Vincristine
,11488768,Ki,"Vinblastine, vincristine and amsacrine at 500 microM significantly (P < 0.05) inhibited DMXAA glucuronidation (Ki = 319, 350 and 230 microM, respectively), but not 6-methylhydroxylation in human liver microsomes.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,350,255425,DB00541,Vincristine
,11488768,Ki,"Vinblastine, vincristine and amsacrine at 500 microM significantly (P < 0.05) inhibited DMXAA glucuronidation (Ki = 319, 350 and 230 microM, respectively), but not 6-methylhydroxylation in human liver microsomes.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,230,255426,DB00541,Vincristine
,11488768,Ki,"Daunorubicin and N-[2-(dimethylamino)-ethyl]acridine-4-carboxamide (DACA) at 100 and 500 microM showed significant (P < 0.05) inhibition of DMXAA 6-methylhydroxylation (Ki = 131 and 0.59 microM, respectively), but not glucuronidation.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,131,255427,DB00541,Vincristine
,11488768,Ki,"Daunorubicin and N-[2-(dimethylamino)-ethyl]acridine-4-carboxamide (DACA) at 100 and 500 microM showed significant (P < 0.05) inhibition of DMXAA 6-methylhydroxylation (Ki = 131 and 0.59 microM, respectively), but not glucuronidation.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,0.59,255428,DB00541,Vincristine
,26838831,serum half-life,"However, poor biopharmaceutical and pharmacokinetic traits of VCS like short serum half-life (12 min), high dosing frequency (1.4 mg/m(2) per week for 4 weeks) and extensive protein binding (75%) limit the clinical potential of VCS in cancer therapy.","Vincristine sulfate loaded dextran microspheres amalgamated with thermosensitive gel offered sustained release and enhanced cytotoxicity in THP-1, human leukemia cells: In vitro and in vivo study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838831/),min,12,255702,DB00541,Vincristine
,26838831,protein binding,"However, poor biopharmaceutical and pharmacokinetic traits of VCS like short serum half-life (12 min), high dosing frequency (1.4 mg/m(2) per week for 4 weeks) and extensive protein binding (75%) limit the clinical potential of VCS in cancer therapy.","Vincristine sulfate loaded dextran microspheres amalgamated with thermosensitive gel offered sustained release and enhanced cytotoxicity in THP-1, human leukemia cells: In vitro and in vivo study. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838831/),%,75,255703,DB00541,Vincristine
,26838831,zeta-potential,Particle size and zeta-potential of VCS-Dextran-MSs were measured to be 6.8 ± 2.4 μm and -18.3 ± 0.11 mV along with the encapsulation efficiency of about 60.4 ± 4.5%.,"Vincristine sulfate loaded dextran microspheres amalgamated with thermosensitive gel offered sustained release and enhanced cytotoxicity in THP-1, human leukemia cells: In vitro and in vivo study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838831/),mv,-,255704,DB00541,Vincristine
,26838831,zeta-potential,Particle size and zeta-potential of VCS-Dextran-MSs were measured to be 6.8 ± 2.4 μm and -18.3 ± 0.11 mV along with the encapsulation efficiency of about 60.4 ± 4.5%.,"Vincristine sulfate loaded dextran microspheres amalgamated with thermosensitive gel offered sustained release and enhanced cytotoxicity in THP-1, human leukemia cells: In vitro and in vivo study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838831/),mv,18.3,255705,DB00541,Vincristine
,7931891,clearance,"Vincristine clearance, estimated by Bayesian methods, was highly variable, with a mean (SD) clearance of 19.9 (14.9) ml/min per kilogram or 482 (342) ml/min per square meter.",Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931891/),[ml] / [kg·min],19.9,259481,DB00541,Vincristine
,7931891,clearance,"Vincristine clearance, estimated by Bayesian methods, was highly variable, with a mean (SD) clearance of 19.9 (14.9) ml/min per kilogram or 482 (342) ml/min per square meter.",Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931891/),[ml] / [meter·min·square],482,259482,DB00541,Vincristine
,19530072,apparent influx clearance,The apparent influx clearance of [(3)H]naloxone across the BBB was 0.305 mL/min/g brain.,Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),[ml] / [brain·g·min],0.305,261249,DB00541,Vincristine
,19530072,apparent elimination half-life,[(3)H]naloxone was eliminated from the brain with an apparent elimination half-life of 15.1 min after microinjection into the parietal cortex area 2 regions of the rat brain.,Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),min,15.1,261250,DB00541,Vincristine
,19530072,apparent efflux clearance,"The apparent efflux clearance of [(3)H]naloxone across the BBB was 0.152 mL/min/g brain, which was calculated from the elimination rate constant (4.79 x 10(-2) min(-1)) and the distribution volume in the brain (3.18 mL/g brain).",Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),[ml] / [brain·g·min],0.152,261251,DB00541,Vincristine
,19530072,elimination rate constant,"The apparent efflux clearance of [(3)H]naloxone across the BBB was 0.152 mL/min/g brain, which was calculated from the elimination rate constant (4.79 x 10(-2) min(-1)) and the distribution volume in the brain (3.18 mL/g brain).",Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),1/[min],4.79 x 10(-2),261252,DB00541,Vincristine
,19530072,distribution volume,"The apparent efflux clearance of [(3)H]naloxone across the BBB was 0.152 mL/min/g brain, which was calculated from the elimination rate constant (4.79 x 10(-2) min(-1)) and the distribution volume in the brain (3.18 mL/g brain).",Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),[ml] / [brain·g],3.18,261253,DB00541,Vincristine
,6498821,systemic clearance,"Navelbine systemic clearance was estimated from the area under the concentration-time curves [1.9 +/- 0.5 (S.D.) liters/hr/kg] and was found to be larger than that of vinblastine (1.1 +/- 0.4 liters/hr/kg) measured under similar conditions (dose, 0.6 mg/kg).",Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),[l] / [h·kg],1.9,261637,DB00541,Vincristine
,6498821,systemic clearance,"Navelbine systemic clearance was estimated from the area under the concentration-time curves [1.9 +/- 0.5 (S.D.) liters/hr/kg] and was found to be larger than that of vinblastine (1.1 +/- 0.4 liters/hr/kg) measured under similar conditions (dose, 0.6 mg/kg).",Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),[l] / [h·kg],1.1,261638,DB00541,Vincristine
,6498821,area under the concentration-time curves,"Navelbine systemic clearance was estimated from the area under the concentration-time curves [1.9 +/- 0.5 (S.D.) liters/hr/kg] and was found to be larger than that of vinblastine (1.1 +/- 0.4 liters/hr/kg) measured under similar conditions (dose, 0.6 mg/kg).",Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),[l] / [h·kg],1.9,261639,DB00541,Vincristine
,6498821,area under the concentration-time curves,"Navelbine systemic clearance was estimated from the area under the concentration-time curves [1.9 +/- 0.5 (S.D.) liters/hr/kg] and was found to be larger than that of vinblastine (1.1 +/- 0.4 liters/hr/kg) measured under similar conditions (dose, 0.6 mg/kg).",Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),[l] / [h·kg],1.1,261640,DB00541,Vincristine
,6498821,Terminal half-lives,Terminal half-lives were 8.9 +/- 2.1 hr for navelbine and 8.1 +/- 2.6 hr for vinblastine.,Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),h,8.9,261641,DB00541,Vincristine
,6498821,Terminal half-lives,Terminal half-lives were 8.9 +/- 2.1 hr for navelbine and 8.1 +/- 2.6 hr for vinblastine.,Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),h,8.1,261642,DB00541,Vincristine
,9074848,overall response rates,Liposomal doxorubicin monotherapy in patients with AIDS-related Kaposi's sarcoma produced overall response rates (complete plus partial) of 43 and 59% in large comparative studies and 67 to 100% in noncomparative studies which included > or = 20 patients.,"Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,43,263580,DB00541,Vincristine
,9074848,overall response rates,Liposomal doxorubicin monotherapy in patients with AIDS-related Kaposi's sarcoma produced overall response rates (complete plus partial) of 43 and 59% in large comparative studies and 67 to 100% in noncomparative studies which included > or = 20 patients.,"Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,59,263581,DB00541,Vincristine
,9074848,overall response rates,Liposomal doxorubicin monotherapy in patients with AIDS-related Kaposi's sarcoma produced overall response rates (complete plus partial) of 43 and 59% in large comparative studies and 67 to 100% in noncomparative studies which included > or = 20 patients.,"Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,67,263582,DB00541,Vincristine
,9074848,overall response rates,"In comparative studies, liposomal doxorubicin was significantly more effective than the combination of standard doxorubicin, bleomycin and vincristine (overall response rates of 43 and 25%, respectively) and bleomycin and vincristine (BV) [overall response rates of 59 and 23%, respectively].","Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,43,263583,DB00541,Vincristine
,9074848,overall response rates,"In comparative studies, liposomal doxorubicin was significantly more effective than the combination of standard doxorubicin, bleomycin and vincristine (overall response rates of 43 and 25%, respectively) and bleomycin and vincristine (BV) [overall response rates of 59 and 23%, respectively].","Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,25,263584,DB00541,Vincristine
,9074848,overall response rates,"In comparative studies, liposomal doxorubicin was significantly more effective than the combination of standard doxorubicin, bleomycin and vincristine (overall response rates of 43 and 25%, respectively) and bleomycin and vincristine (BV) [overall response rates of 59 and 23%, respectively].","Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,59,263585,DB00541,Vincristine
,9074848,overall response rates,"In comparative studies, liposomal doxorubicin was significantly more effective than the combination of standard doxorubicin, bleomycin and vincristine (overall response rates of 43 and 25%, respectively) and bleomycin and vincristine (BV) [overall response rates of 59 and 23%, respectively].","Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,23,263586,DB00541,Vincristine
,12394263,T/C,VCR-Lip at a dose of 1.0 mg/kg (dose near the maximum tolerated dose) led to partial remissions in the MX1 tumor xenograft model (T/C=3.9%).,Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394263/),%,3.9,264594,DB00541,Vincristine
,12394263,T/C,VCR-Conv at an equitoxic dose of 0.6 mg/kg produced only a tumor growth inhibition (T/C=7.0%).,Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394263/),%,7.0,264595,DB00541,Vincristine
,12394263,T/C,"In LXFS 650 tumor-bearing mice, VCR-Lip was highly active at doses of 0.75 (T/C=0.7%) and 1.0 (T/C=0.0%) mg/kg, and complete tumor regressions were observed.",Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394263/),%,0.7,264596,DB00541,Vincristine
,12394263,T/C,"In LXFS 650 tumor-bearing mice, VCR-Lip was highly active at doses of 0.75 (T/C=0.7%) and 1.0 (T/C=0.0%) mg/kg, and complete tumor regressions were observed.",Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394263/),%,0.0,264597,DB00541,Vincristine
,12394263,T/C,"In contrast, equitoxic doses of VCR-Conv (0.6 mg/kg) resulted only in less pronounced tumor remissions (T/C=4.1%).",Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394263/),%,4.1,264598,DB00541,Vincristine
,12394263,plasma AUC,The PK study revealed that VCR-Lip achieved an over 10-fold higher plasma AUC (22.6 microg x h/ml) than VCR-Conv (2.16 microg x h/ml).,Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394263/),[h·μg] / [ml],22.6,264599,DB00541,Vincristine
,12394263,plasma AUC,The PK study revealed that VCR-Lip achieved an over 10-fold higher plasma AUC (22.6 microg x h/ml) than VCR-Conv (2.16 microg x h/ml).,Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394263/),[h·μg] / [ml],2.16,264600,DB00541,Vincristine
,15197807,steady-state plasma concentration,The steady-state plasma concentration of VCR during continuous infusion ranged from 1 to 3 microg/L in all patients.,Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15197807/),[μg] / [l],1 to 3,265714,DB00541,Vincristine
,22337718,Total clearance,Total clearance was 9.43 mL/h and Vd(ss) was 9.61 l.,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],9.43,266008,DB00541,Vincristine
,22337718,Vd(ss),Total clearance was 9.43 mL/h and Vd(ss) was 9.61 l.,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),l,9.61,266009,DB00541,Vincristine
,22337718,clearance,Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],8.21,266010,DB00541,Vincristine
,22337718,clearance,Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],12.68,266011,DB00541,Vincristine
,22337718,t(1/2β),Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),d,30.7,266012,DB00541,Vincristine
,22337718,t(1/2β),Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),d,24.7,266013,DB00541,Vincristine
,27613245,elimination t½,VCR demonstrated a rapid distribution phase (6-8 h) followed by a slower elimination phase with a mean elimination t½ of ~ 14 h.,The effect of increased lipoproteins levels on the disposition of vincristine in rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613245/),h,14,267377,DB00541,Vincristine
,27613245,Vc,It showed a relatively small Vc (~0.17 L/Kg) and a larger Vβ (1.53 L/Kg) indicating good tissue distribution.,The effect of increased lipoproteins levels on the disposition of vincristine in rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613245/),[l] / [kg],0.17,267378,DB00541,Vincristine
,27613245,Vβ,It showed a relatively small Vc (~0.17 L/Kg) and a larger Vβ (1.53 L/Kg) indicating good tissue distribution.,The effect of increased lipoproteins levels on the disposition of vincristine in rat. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613245/),[l] / [kg],1.53,267379,DB00541,Vincristine
,2735930,maximal concentration,"At this dose, the maximal concentration in plasma was 24 microM, with rapid elimination such that plasma concentrations reported to modulate resistance in vitro (approximately 5-10 microM) were maintained for less than 60 min.",Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735930/),μM,24,273488,DB00541,Vincristine
,2735930,T1/2,"In small intestine, 8-fold greater levels of VCR were determined 24 hr after VCR administration, and this was associated with in increase in T1/2 for elimination from 350 to 913 min.",Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735930/),min,350,273489,DB00541,Vincristine
,2735930,T1/2,"In small intestine, 8-fold greater levels of VCR were determined 24 hr after VCR administration, and this was associated with in increase in T1/2 for elimination from 350 to 913 min.",Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735930/),min,91,273490,DB00541,Vincristine
,2735930,T1/2,"In small intestine, 8-fold greater levels of VCR were determined 24 hr after VCR administration, and this was associated with in increase in T1/2 for elimination from 350 to 913 min.",Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735930/),min,3,273491,DB00541,Vincristine
,8339389,Peak plasma DOX levels,"Peak plasma DOX levels were higher after the bolus injection than after continuous administration (1509 +/- 80 ng/ml vs 11.6 +/- 1.8 ng/ml, respectively), whereas the plasma area under the curve (AUC) levels were similar.",Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339389/),[ng] / [ml],1509,274180,DB00541,Vincristine
,8339389,Peak plasma DOX levels,"Peak plasma DOX levels were higher after the bolus injection than after continuous administration (1509 +/- 80 ng/ml vs 11.6 +/- 1.8 ng/ml, respectively), whereas the plasma area under the curve (AUC) levels were similar.",Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339389/),[ng] / [ml],11.6,274181,DB00541,Vincristine
,8339389,Maximum DOX cellular concentrations,Maximum DOX cellular concentrations were 8629 +/- 2902 ng/10(9) cells (bolus injection) and 2745 +/- 673 ng/10(9) cells (96 h infusion).,Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339389/),[ng] / [10(9)·cells],8629,274182,DB00541,Vincristine
,8339389,Maximum DOX cellular concentrations,Maximum DOX cellular concentrations were 8629 +/- 2902 ng/10(9) cells (bolus injection) and 2745 +/- 673 ng/10(9) cells (96 h infusion).,Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339389/),[ng] / [10(9)·cells],2745,274183,DB00541,Vincristine
